Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,2493353,elimination half-life,Estimated mean elimination half-life of glyburide was 3.3 +/- 1.1 hours for EM and 2.5 +/- 0.4 hours for PM.,The metabolism of glyburide in subjects of known debrisoquin phenotype. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2493353/),h,3.3,2489,DB01124,Tolbutamide
,2493353,elimination half-life,Estimated mean elimination half-life of glyburide was 3.3 +/- 1.1 hours for EM and 2.5 +/- 0.4 hours for PM.,The metabolism of glyburide in subjects of known debrisoquin phenotype. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2493353/),h,2.5,2490,DB01124,Tolbutamide
,2493353,apparent elimination half-life,"In one subject (EM), with reduced excretion of 30H, glyburide was detected in plasma at 24 and 30 hours and the apparent elimination half-life was 9.3 hours.",The metabolism of glyburide in subjects of known debrisoquin phenotype. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2493353/),h,9.3,2491,DB01124,Tolbutamide
,9678539,half-life,The half-life of serum tolbutamide decreased from 46 to 6 h.,Prolonged elimination of tolbutamide in a premature newborn with hyperinsulinaemic hypoglycaemia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9678539/),h,46,4018,DB01124,Tolbutamide
,9678539,half-life,The half-life of serum tolbutamide decreased from 46 to 6 h.,Prolonged elimination of tolbutamide in a premature newborn with hyperinsulinaemic hypoglycaemia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9678539/),h,6,4019,DB01124,Tolbutamide
,33746741,half-maximal inhibitory concentration,"The in vitro results revealed that the half-maximal inhibitory concentration values of bupropion and tolbutamide in RLMs were 8.79 and 20.17 μM, respectively, indicating that poziotinib showed varying degrees of inhibition toward cyp2b1 and cyp2c11.",Inhibition and Induction by Poziotinib of Different Rat Cytochrome P450 Enzymes In Vivo and in an In Vitro Cocktail Method. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33746741/),μM,8.79,5916,DB01124,Tolbutamide
,33746741,half-maximal inhibitory concentration,"The in vitro results revealed that the half-maximal inhibitory concentration values of bupropion and tolbutamide in RLMs were 8.79 and 20.17 μM, respectively, indicating that poziotinib showed varying degrees of inhibition toward cyp2b1 and cyp2c11.",Inhibition and Induction by Poziotinib of Different Rat Cytochrome P450 Enzymes In Vivo and in an In Vitro Cocktail Method. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33746741/),μM,20.17,5917,DB01124,Tolbutamide
,33746741,Ki,"Poziotinib was a competitive inhibitor of cyp2b1 and cyp2c11, with Ki values of 16.18 and 17.66 μM, respectively.",Inhibition and Induction by Poziotinib of Different Rat Cytochrome P450 Enzymes In Vivo and in an In Vitro Cocktail Method. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33746741/),μM,16.18,5918,DB01124,Tolbutamide
,33746741,Ki,"Poziotinib was a competitive inhibitor of cyp2b1 and cyp2c11, with Ki values of 16.18 and 17.66 μM, respectively.",Inhibition and Induction by Poziotinib of Different Rat Cytochrome P450 Enzymes In Vivo and in an In Vitro Cocktail Method. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33746741/),μM,17.66,5919,DB01124,Tolbutamide
,23138519,flow rate,"The analytes were extracted by using liquid-liquid extraction procedure and separated on a reverse phase C18 column (50 mm×3 mm i.d., 4.6 µ) using methanol: 2 mM ammonium acetate buffer, pH 4.0 as mobile phase at a flow rate 1 mL/min in gradient mode.","Simultaneous determination of methotrexate, dasatinib and its active metabolite N- deshydroxyethyl dasatinib in rat plasma by LC-MS/MS: method validation and application to pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23138519/),[ml] / [min],1,7934,DB01124,Tolbutamide
>,23138519,recoveries,The recoveries from spiked control samples were > 79% for all analytes and internal standard Intra- and Interday accuracy and precision of validated method were within the acceptable limits of < 15% at all concentration.,"Simultaneous determination of methotrexate, dasatinib and its active metabolite N- deshydroxyethyl dasatinib in rat plasma by LC-MS/MS: method validation and application to pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23138519/),%,79,7935,DB01124,Tolbutamide
,25594893,flow rate,"Chromatographic separation of analytes was performed on YMC pack ODS AM (150 mm × 4.6 mm, 5 μm) column under gradient conditions with acetonitrile:0.1% formic acid buffer as the mobile phases at a flow rate of 1 ml/min.","Simultaneous quantification of lenalidomide, ibrutinib and its active metabolite PCI-45227 in rat plasma by LC-MS/MS: application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25594893/),[ml] / [min],1,10969,DB01124,Tolbutamide
,25594893,extraction recovery,"Mean extraction recovery for ibrutinib, PCI-45227, lenalidomide and IS of 75.2%, 84.5%, 97.3% and 92.3% were consistent across low, medium, and high QC levels.","Simultaneous quantification of lenalidomide, ibrutinib and its active metabolite PCI-45227 in rat plasma by LC-MS/MS: application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25594893/),%,75.2,10970,DB01124,Tolbutamide
,25594893,extraction recovery,"Mean extraction recovery for ibrutinib, PCI-45227, lenalidomide and IS of 75.2%, 84.5%, 97.3% and 92.3% were consistent across low, medium, and high QC levels.","Simultaneous quantification of lenalidomide, ibrutinib and its active metabolite PCI-45227 in rat plasma by LC-MS/MS: application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25594893/),%,84.5,10971,DB01124,Tolbutamide
,25594893,extraction recovery,"Mean extraction recovery for ibrutinib, PCI-45227, lenalidomide and IS of 75.2%, 84.5%, 97.3% and 92.3% were consistent across low, medium, and high QC levels.","Simultaneous quantification of lenalidomide, ibrutinib and its active metabolite PCI-45227 in rat plasma by LC-MS/MS: application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25594893/),%,97.3,10972,DB01124,Tolbutamide
,25594893,extraction recovery,"Mean extraction recovery for ibrutinib, PCI-45227, lenalidomide and IS of 75.2%, 84.5%, 97.3% and 92.3% were consistent across low, medium, and high QC levels.","Simultaneous quantification of lenalidomide, ibrutinib and its active metabolite PCI-45227 in rat plasma by LC-MS/MS: application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25594893/),%,92.3,10973,DB01124,Tolbutamide
,24944160,flow rate,"Chromatographic separation was achieved with 5 mm ammonium acetate (pH 6.5)-acetonitrile (35:65, v/v) at a flow rate of 0.60 mL/min on an Atlantis dC18 column with a total run time 3.0 min.",Development of an LC-MS/MS method for determination of bicalutamide on dried blood spots: application to pharmacokinetic study in mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24944160/),[ml] / [min],0.60,11057,DB01124,Tolbutamide
,24944160,total run time,"Chromatographic separation was achieved with 5 mm ammonium acetate (pH 6.5)-acetonitrile (35:65, v/v) at a flow rate of 0.60 mL/min on an Atlantis dC18 column with a total run time 3.0 min.",Development of an LC-MS/MS method for determination of bicalutamide on dried blood spots: application to pharmacokinetic study in mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24944160/),min,3.0,11058,DB01124,Tolbutamide
,22961730,flow rate,"Chromatographic separation was performed on a YMC Hydrosphere C18 column with an isocratic mobile phase, which consisted of 10 mm ammonium formate buffer (adjusted to pH 5.0 with formic acid)-methanol (60:40, v/v) at a flow rate of 0.4 mL/min.",Rapid and sensitive LC-MS/MS method for determination of megestrol acetate in human plasma: application to a human pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22961730/),[ml] / [min],0.4,11104,DB01124,Tolbutamide
>,22961730,signal-to-noise ratio,The achieved lower limit of quantitation (LLOQ) was 1 ng/mL (signal-to-noise ratio > 10) and the standard calibration curve for megestrol acetate was linear (r > 0.99) over the studied concentration range (1-2000 ng/mL).,Rapid and sensitive LC-MS/MS method for determination of megestrol acetate in human plasma: application to a human pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22961730/),,10,11105,DB01124,Tolbutamide
,30654691,T1/2,"3. The plasma concentration reached the Cmax within 1.0 h (inhalation) and descended with the T1/2 of 8.53 and 6.69 h for inhalation and i.v. administration, respectively.",Pharmacokinetics behaviors of l-menthol after inhalation and intravenous injection in rats and its inhibition effects on CYP450 enzymes in rat liver microsomes. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30654691/),h,8.53,11633,DB01124,Tolbutamide
,30654691,T1/2,"3. The plasma concentration reached the Cmax within 1.0 h (inhalation) and descended with the T1/2 of 8.53 and 6.69 h for inhalation and i.v. administration, respectively.",Pharmacokinetics behaviors of l-menthol after inhalation and intravenous injection in rats and its inhibition effects on CYP450 enzymes in rat liver microsomes. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30654691/),h,6.69,11634,DB01124,Tolbutamide
,30654691,IC50,"IC50 for inhibition of l-menthol on CYP 450 enzymes were 4.35 μM for 2D4, 8.67 μM for 1A2, 13.02 μM for 3A1, 14.78 μM for 2D1/2, 234.9 μM for 2C11 and 525.4 μM for 2E1, respectively.",Pharmacokinetics behaviors of l-menthol after inhalation and intravenous injection in rats and its inhibition effects on CYP450 enzymes in rat liver microsomes. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30654691/),μM,4.35,11635,DB01124,Tolbutamide
,30654691,IC50,"IC50 for inhibition of l-menthol on CYP 450 enzymes were 4.35 μM for 2D4, 8.67 μM for 1A2, 13.02 μM for 3A1, 14.78 μM for 2D1/2, 234.9 μM for 2C11 and 525.4 μM for 2E1, respectively.",Pharmacokinetics behaviors of l-menthol after inhalation and intravenous injection in rats and its inhibition effects on CYP450 enzymes in rat liver microsomes. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30654691/),μM,8.67,11636,DB01124,Tolbutamide
,30654691,IC50,"IC50 for inhibition of l-menthol on CYP 450 enzymes were 4.35 μM for 2D4, 8.67 μM for 1A2, 13.02 μM for 3A1, 14.78 μM for 2D1/2, 234.9 μM for 2C11 and 525.4 μM for 2E1, respectively.",Pharmacokinetics behaviors of l-menthol after inhalation and intravenous injection in rats and its inhibition effects on CYP450 enzymes in rat liver microsomes. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30654691/),μM,13.02,11637,DB01124,Tolbutamide
,30654691,IC50,"IC50 for inhibition of l-menthol on CYP 450 enzymes were 4.35 μM for 2D4, 8.67 μM for 1A2, 13.02 μM for 3A1, 14.78 μM for 2D1/2, 234.9 μM for 2C11 and 525.4 μM for 2E1, respectively.",Pharmacokinetics behaviors of l-menthol after inhalation and intravenous injection in rats and its inhibition effects on CYP450 enzymes in rat liver microsomes. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30654691/),μM,14.78,11638,DB01124,Tolbutamide
,30654691,IC50,"IC50 for inhibition of l-menthol on CYP 450 enzymes were 4.35 μM for 2D4, 8.67 μM for 1A2, 13.02 μM for 3A1, 14.78 μM for 2D1/2, 234.9 μM for 2C11 and 525.4 μM for 2E1, respectively.",Pharmacokinetics behaviors of l-menthol after inhalation and intravenous injection in rats and its inhibition effects on CYP450 enzymes in rat liver microsomes. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30654691/),μM,234.9,11639,DB01124,Tolbutamide
,30654691,IC50,"IC50 for inhibition of l-menthol on CYP 450 enzymes were 4.35 μM for 2D4, 8.67 μM for 1A2, 13.02 μM for 3A1, 14.78 μM for 2D1/2, 234.9 μM for 2C11 and 525.4 μM for 2E1, respectively.",Pharmacokinetics behaviors of l-menthol after inhalation and intravenous injection in rats and its inhibition effects on CYP450 enzymes in rat liver microsomes. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30654691/),μM,525.4,11640,DB01124,Tolbutamide
,12369449,flow rate,The mobile phase comprised of 10 mM potassium dihydrogen ortho phosphate (pH 3.2) and acetonitrile (50:50 v/v) with a flow rate of 1 ml/min.,Validated HPLC method for the determination of celecoxib in human serum and its application in a clinical pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12369449/),[ml] / [min],1,19839,DB01124,Tolbutamide
,12369449,Retention times,"Retention times of celecoxib and tolbutamide were 9.6 and 3.5 min, respectively.",Validated HPLC method for the determination of celecoxib in human serum and its application in a clinical pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12369449/),min,9.6,19840,DB01124,Tolbutamide
,12369449,Retention times,"Retention times of celecoxib and tolbutamide were 9.6 and 3.5 min, respectively.",Validated HPLC method for the determination of celecoxib in human serum and its application in a clinical pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12369449/),min,3.5,19841,DB01124,Tolbutamide
,32215046,flow rate,"The chromatographic separation was performed on a Waters XBridge™ C18 column (2.1 mm × 100 mm, 3.5 μm) using a gradient elution with the mobile phase consisting of acetonitrile and water (containing 0.1% formic acid) at a flow rate of 0.3 mL/min.",HPLC-MS/MS Analysis of Aconiti Lateralis Radix Praeparata and Its Combination with Red Ginseng Effect on Rat CYP450 Activities Using the Cocktail Approach. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32215046/),[ml] / [min],0.3,20924,DB01124,Tolbutamide
,11673747,oral clearance,Long-term St John's wort administration caused a significant (P <.05) increase in oral clearance of midazolam from 121.8 +/- 70.7 to 254.5 +/- 127.8 and a corresponding significant decline in oral bioavailability from 0.28 +/- 0.15 to 0.17 +/- 0.06.,The effects of St John's wort (Hypericum perforatum) on human cytochrome P450 activity. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11673747/),,121.8,21797,DB01124,Tolbutamide
,11673747,oral clearance,Long-term St John's wort administration caused a significant (P <.05) increase in oral clearance of midazolam from 121.8 +/- 70.7 to 254.5 +/- 127.8 and a corresponding significant decline in oral bioavailability from 0.28 +/- 0.15 to 0.17 +/- 0.06.,The effects of St John's wort (Hypericum perforatum) on human cytochrome P450 activity. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11673747/),,254.5,21798,DB01124,Tolbutamide
,11673747,oral bioavailability,Long-term St John's wort administration caused a significant (P <.05) increase in oral clearance of midazolam from 121.8 +/- 70.7 to 254.5 +/- 127.8 and a corresponding significant decline in oral bioavailability from 0.28 +/- 0.15 to 0.17 +/- 0.06.,The effects of St John's wort (Hypericum perforatum) on human cytochrome P450 activity. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11673747/),,0.28,21799,DB01124,Tolbutamide
,11673747,oral bioavailability,Long-term St John's wort administration caused a significant (P <.05) increase in oral clearance of midazolam from 121.8 +/- 70.7 to 254.5 +/- 127.8 and a corresponding significant decline in oral bioavailability from 0.28 +/- 0.15 to 0.17 +/- 0.06.,The effects of St John's wort (Hypericum perforatum) on human cytochrome P450 activity. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11673747/),,0.17,21800,DB01124,Tolbutamide
,31662775,AUC(0-24),"The study showed that AUC(0-24) and AUC(0-∞) of midazolam (CYP3A4) in NXT coadministration group (283.7 ± 65.2 h·ng·mL-1 and 292.0 ± 75.1 h·ng·mL-1 in group B; 295.7 ± 62.7 h·ng·mL-1 and 299.5 ± 60.0 h·ng·mL-1 in group C) were significantly decreased as compared to another group (416.8 ± 82.3 h·ng·mL-1 and 424.9 ± 77.9 h·ng·mL-1 in group A), while that of dextromethorphan (CYP2D6) showed an opposite tendency (540.7 ± 119.7 h·ng·mL-1 and 595.3 ± 122.2 h·ng·mL-1 in group A, 760.6 ± 184.9 h·ng·mL-1 and 788.7 ± 211.0 h·ng·mL-1 in group B, and 734.3 ± 118.5 h·ng·mL-1 and 757.2 ± 105.4 h·ng·mL-1 in group C).",Effect of Naoxintong Capsules on the Activities of CYP450 and Metabolism of Metoprolol Tartrate in Rats Evaluated by Probe Cocktail and Pharmacokinetic Methods. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31662775/),[h·ng] / [ml],283.7,23877,DB01124,Tolbutamide
,31662775,AUC(0-24),"The study showed that AUC(0-24) and AUC(0-∞) of midazolam (CYP3A4) in NXT coadministration group (283.7 ± 65.2 h·ng·mL-1 and 292.0 ± 75.1 h·ng·mL-1 in group B; 295.7 ± 62.7 h·ng·mL-1 and 299.5 ± 60.0 h·ng·mL-1 in group C) were significantly decreased as compared to another group (416.8 ± 82.3 h·ng·mL-1 and 424.9 ± 77.9 h·ng·mL-1 in group A), while that of dextromethorphan (CYP2D6) showed an opposite tendency (540.7 ± 119.7 h·ng·mL-1 and 595.3 ± 122.2 h·ng·mL-1 in group A, 760.6 ± 184.9 h·ng·mL-1 and 788.7 ± 211.0 h·ng·mL-1 in group B, and 734.3 ± 118.5 h·ng·mL-1 and 757.2 ± 105.4 h·ng·mL-1 in group C).",Effect of Naoxintong Capsules on the Activities of CYP450 and Metabolism of Metoprolol Tartrate in Rats Evaluated by Probe Cocktail and Pharmacokinetic Methods. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31662775/),[h·ng] / [ml],295.7,23878,DB01124,Tolbutamide
,31662775,AUC(0-24),"The study showed that AUC(0-24) and AUC(0-∞) of midazolam (CYP3A4) in NXT coadministration group (283.7 ± 65.2 h·ng·mL-1 and 292.0 ± 75.1 h·ng·mL-1 in group B; 295.7 ± 62.7 h·ng·mL-1 and 299.5 ± 60.0 h·ng·mL-1 in group C) were significantly decreased as compared to another group (416.8 ± 82.3 h·ng·mL-1 and 424.9 ± 77.9 h·ng·mL-1 in group A), while that of dextromethorphan (CYP2D6) showed an opposite tendency (540.7 ± 119.7 h·ng·mL-1 and 595.3 ± 122.2 h·ng·mL-1 in group A, 760.6 ± 184.9 h·ng·mL-1 and 788.7 ± 211.0 h·ng·mL-1 in group B, and 734.3 ± 118.5 h·ng·mL-1 and 757.2 ± 105.4 h·ng·mL-1 in group C).",Effect of Naoxintong Capsules on the Activities of CYP450 and Metabolism of Metoprolol Tartrate in Rats Evaluated by Probe Cocktail and Pharmacokinetic Methods. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31662775/),[h·ng] / [ml],416.8,23879,DB01124,Tolbutamide
,31662775,AUC(0-24),"The study showed that AUC(0-24) and AUC(0-∞) of midazolam (CYP3A4) in NXT coadministration group (283.7 ± 65.2 h·ng·mL-1 and 292.0 ± 75.1 h·ng·mL-1 in group B; 295.7 ± 62.7 h·ng·mL-1 and 299.5 ± 60.0 h·ng·mL-1 in group C) were significantly decreased as compared to another group (416.8 ± 82.3 h·ng·mL-1 and 424.9 ± 77.9 h·ng·mL-1 in group A), while that of dextromethorphan (CYP2D6) showed an opposite tendency (540.7 ± 119.7 h·ng·mL-1 and 595.3 ± 122.2 h·ng·mL-1 in group A, 760.6 ± 184.9 h·ng·mL-1 and 788.7 ± 211.0 h·ng·mL-1 in group B, and 734.3 ± 118.5 h·ng·mL-1 and 757.2 ± 105.4 h·ng·mL-1 in group C).",Effect of Naoxintong Capsules on the Activities of CYP450 and Metabolism of Metoprolol Tartrate in Rats Evaluated by Probe Cocktail and Pharmacokinetic Methods. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31662775/),[h·ng] / [ml],540.7,23880,DB01124,Tolbutamide
,31662775,AUC(0-∞),"The study showed that AUC(0-24) and AUC(0-∞) of midazolam (CYP3A4) in NXT coadministration group (283.7 ± 65.2 h·ng·mL-1 and 292.0 ± 75.1 h·ng·mL-1 in group B; 295.7 ± 62.7 h·ng·mL-1 and 299.5 ± 60.0 h·ng·mL-1 in group C) were significantly decreased as compared to another group (416.8 ± 82.3 h·ng·mL-1 and 424.9 ± 77.9 h·ng·mL-1 in group A), while that of dextromethorphan (CYP2D6) showed an opposite tendency (540.7 ± 119.7 h·ng·mL-1 and 595.3 ± 122.2 h·ng·mL-1 in group A, 760.6 ± 184.9 h·ng·mL-1 and 788.7 ± 211.0 h·ng·mL-1 in group B, and 734.3 ± 118.5 h·ng·mL-1 and 757.2 ± 105.4 h·ng·mL-1 in group C).",Effect of Naoxintong Capsules on the Activities of CYP450 and Metabolism of Metoprolol Tartrate in Rats Evaluated by Probe Cocktail and Pharmacokinetic Methods. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31662775/),[h·ng] / [ml],292.0,23881,DB01124,Tolbutamide
,31662775,AUC(0-∞),"The study showed that AUC(0-24) and AUC(0-∞) of midazolam (CYP3A4) in NXT coadministration group (283.7 ± 65.2 h·ng·mL-1 and 292.0 ± 75.1 h·ng·mL-1 in group B; 295.7 ± 62.7 h·ng·mL-1 and 299.5 ± 60.0 h·ng·mL-1 in group C) were significantly decreased as compared to another group (416.8 ± 82.3 h·ng·mL-1 and 424.9 ± 77.9 h·ng·mL-1 in group A), while that of dextromethorphan (CYP2D6) showed an opposite tendency (540.7 ± 119.7 h·ng·mL-1 and 595.3 ± 122.2 h·ng·mL-1 in group A, 760.6 ± 184.9 h·ng·mL-1 and 788.7 ± 211.0 h·ng·mL-1 in group B, and 734.3 ± 118.5 h·ng·mL-1 and 757.2 ± 105.4 h·ng·mL-1 in group C).",Effect of Naoxintong Capsules on the Activities of CYP450 and Metabolism of Metoprolol Tartrate in Rats Evaluated by Probe Cocktail and Pharmacokinetic Methods. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31662775/),[h·ng] / [ml],416.8,23882,DB01124,Tolbutamide
,31662775,AUC(0-∞),"The study showed that AUC(0-24) and AUC(0-∞) of midazolam (CYP3A4) in NXT coadministration group (283.7 ± 65.2 h·ng·mL-1 and 292.0 ± 75.1 h·ng·mL-1 in group B; 295.7 ± 62.7 h·ng·mL-1 and 299.5 ± 60.0 h·ng·mL-1 in group C) were significantly decreased as compared to another group (416.8 ± 82.3 h·ng·mL-1 and 424.9 ± 77.9 h·ng·mL-1 in group A), while that of dextromethorphan (CYP2D6) showed an opposite tendency (540.7 ± 119.7 h·ng·mL-1 and 595.3 ± 122.2 h·ng·mL-1 in group A, 760.6 ± 184.9 h·ng·mL-1 and 788.7 ± 211.0 h·ng·mL-1 in group B, and 734.3 ± 118.5 h·ng·mL-1 and 757.2 ± 105.4 h·ng·mL-1 in group C).",Effect of Naoxintong Capsules on the Activities of CYP450 and Metabolism of Metoprolol Tartrate in Rats Evaluated by Probe Cocktail and Pharmacokinetic Methods. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31662775/),[h·ng] / [ml],424.9,23883,DB01124,Tolbutamide
,31662775,AUC(0-∞),"The study showed that AUC(0-24) and AUC(0-∞) of midazolam (CYP3A4) in NXT coadministration group (283.7 ± 65.2 h·ng·mL-1 and 292.0 ± 75.1 h·ng·mL-1 in group B; 295.7 ± 62.7 h·ng·mL-1 and 299.5 ± 60.0 h·ng·mL-1 in group C) were significantly decreased as compared to another group (416.8 ± 82.3 h·ng·mL-1 and 424.9 ± 77.9 h·ng·mL-1 in group A), while that of dextromethorphan (CYP2D6) showed an opposite tendency (540.7 ± 119.7 h·ng·mL-1 and 595.3 ± 122.2 h·ng·mL-1 in group A, 760.6 ± 184.9 h·ng·mL-1 and 788.7 ± 211.0 h·ng·mL-1 in group B, and 734.3 ± 118.5 h·ng·mL-1 and 757.2 ± 105.4 h·ng·mL-1 in group C).",Effect of Naoxintong Capsules on the Activities of CYP450 and Metabolism of Metoprolol Tartrate in Rats Evaluated by Probe Cocktail and Pharmacokinetic Methods. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31662775/),[h·ng] / [ml],540.7,23884,DB01124,Tolbutamide
,31662775,AUC(0-∞),"The study showed that AUC(0-24) and AUC(0-∞) of midazolam (CYP3A4) in NXT coadministration group (283.7 ± 65.2 h·ng·mL-1 and 292.0 ± 75.1 h·ng·mL-1 in group B; 295.7 ± 62.7 h·ng·mL-1 and 299.5 ± 60.0 h·ng·mL-1 in group C) were significantly decreased as compared to another group (416.8 ± 82.3 h·ng·mL-1 and 424.9 ± 77.9 h·ng·mL-1 in group A), while that of dextromethorphan (CYP2D6) showed an opposite tendency (540.7 ± 119.7 h·ng·mL-1 and 595.3 ± 122.2 h·ng·mL-1 in group A, 760.6 ± 184.9 h·ng·mL-1 and 788.7 ± 211.0 h·ng·mL-1 in group B, and 734.3 ± 118.5 h·ng·mL-1 and 757.2 ± 105.4 h·ng·mL-1 in group C).",Effect of Naoxintong Capsules on the Activities of CYP450 and Metabolism of Metoprolol Tartrate in Rats Evaluated by Probe Cocktail and Pharmacokinetic Methods. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31662775/),[h·ng] / [ml],595.3,23885,DB01124,Tolbutamide
,31662775,AUC(0-∞),"The study showed that AUC(0-24) and AUC(0-∞) of midazolam (CYP3A4) in NXT coadministration group (283.7 ± 65.2 h·ng·mL-1 and 292.0 ± 75.1 h·ng·mL-1 in group B; 295.7 ± 62.7 h·ng·mL-1 and 299.5 ± 60.0 h·ng·mL-1 in group C) were significantly decreased as compared to another group (416.8 ± 82.3 h·ng·mL-1 and 424.9 ± 77.9 h·ng·mL-1 in group A), while that of dextromethorphan (CYP2D6) showed an opposite tendency (540.7 ± 119.7 h·ng·mL-1 and 595.3 ± 122.2 h·ng·mL-1 in group A, 760.6 ± 184.9 h·ng·mL-1 and 788.7 ± 211.0 h·ng·mL-1 in group B, and 734.3 ± 118.5 h·ng·mL-1 and 757.2 ± 105.4 h·ng·mL-1 in group C).",Effect of Naoxintong Capsules on the Activities of CYP450 and Metabolism of Metoprolol Tartrate in Rats Evaluated by Probe Cocktail and Pharmacokinetic Methods. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31662775/),[h·ng] / [ml],760.6,23886,DB01124,Tolbutamide
,31662775,AUC(0-∞),"The study showed that AUC(0-24) and AUC(0-∞) of midazolam (CYP3A4) in NXT coadministration group (283.7 ± 65.2 h·ng·mL-1 and 292.0 ± 75.1 h·ng·mL-1 in group B; 295.7 ± 62.7 h·ng·mL-1 and 299.5 ± 60.0 h·ng·mL-1 in group C) were significantly decreased as compared to another group (416.8 ± 82.3 h·ng·mL-1 and 424.9 ± 77.9 h·ng·mL-1 in group A), while that of dextromethorphan (CYP2D6) showed an opposite tendency (540.7 ± 119.7 h·ng·mL-1 and 595.3 ± 122.2 h·ng·mL-1 in group A, 760.6 ± 184.9 h·ng·mL-1 and 788.7 ± 211.0 h·ng·mL-1 in group B, and 734.3 ± 118.5 h·ng·mL-1 and 757.2 ± 105.4 h·ng·mL-1 in group C).",Effect of Naoxintong Capsules on the Activities of CYP450 and Metabolism of Metoprolol Tartrate in Rats Evaluated by Probe Cocktail and Pharmacokinetic Methods. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31662775/),[h·ng] / [ml],788.7,23887,DB01124,Tolbutamide
,31175627,inhibition constant (Ki),"Honokiol inhibited the formation of acetaminophen from phenacetin and 4-hydroxytolbutamide from tolbutamide in RLMs, with inhibition constant (Ki) values of 1.6 μM and 16.5 μM, respectively.","Inhibition of Rat CYP1A2 and CYP2C11 by Honokiol, a Component of Traditional Chinese Medicine. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31175627/),μM,1.6,32654,DB01124,Tolbutamide
,31175627,inhibition constant (Ki),"Honokiol inhibited the formation of acetaminophen from phenacetin and 4-hydroxytolbutamide from tolbutamide in RLMs, with inhibition constant (Ki) values of 1.6 μM and 16.5 μM, respectively.","Inhibition of Rat CYP1A2 and CYP2C11 by Honokiol, a Component of Traditional Chinese Medicine. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31175627/),μM,16.5,32655,DB01124,Tolbutamide
,14661866,area under the plasma concentration-time curves (AUC),"Consequently, the area under the plasma concentration-time curves (AUC) was significantly higher in mild (p<0.05) and medium (p<0.01) folate-induced renal failure rabbits (i.e., 2906 microg/mL x h for mild renal failure and 4074 microg/mL x h for moderate renal failure) than that in normal rabbits (i.e., 2295 microg/mL x h).",Pharmacokinetics of tolbutamide after oral administration to rabbits with folate-induced renal failure. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14661866/),[μg] / [h·ml],2906,33252,DB01124,Tolbutamide
,14661866,area under the plasma concentration-time curves (AUC),"Consequently, the area under the plasma concentration-time curves (AUC) was significantly higher in mild (p<0.05) and medium (p<0.01) folate-induced renal failure rabbits (i.e., 2906 microg/mL x h for mild renal failure and 4074 microg/mL x h for moderate renal failure) than that in normal rabbits (i.e., 2295 microg/mL x h).",Pharmacokinetics of tolbutamide after oral administration to rabbits with folate-induced renal failure. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14661866/),[μg] / [h·ml],4074,33253,DB01124,Tolbutamide
,14661866,area under the plasma concentration-time curves (AUC),"Consequently, the area under the plasma concentration-time curves (AUC) was significantly higher in mild (p<0.05) and medium (p<0.01) folate-induced renal failure rabbits (i.e., 2906 microg/mL x h for mild renal failure and 4074 microg/mL x h for moderate renal failure) than that in normal rabbits (i.e., 2295 microg/mL x h).",Pharmacokinetics of tolbutamide after oral administration to rabbits with folate-induced renal failure. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14661866/),[μg] / [h·ml],2295,33254,DB01124,Tolbutamide
,14661866,elimination rate constant (Kel),"The elimination rate constant (Kel) of tolbutamide was significantly decreased in medium renal failure rabbits (i.e., 0.027 h(-1)) than that in normal rabbits (i.e., 0.044 h(-1)); As a result, the terminal half-life of tolbutamide in medium folate-induced renal failure rabbits (i.e., 25.5 h) was significantly longer (p<0.01) than that in normal rabbits (i.e., 15.7 h).",Pharmacokinetics of tolbutamide after oral administration to rabbits with folate-induced renal failure. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14661866/),1/[h],0.027,33255,DB01124,Tolbutamide
,14661866,elimination rate constant (Kel),"The elimination rate constant (Kel) of tolbutamide was significantly decreased in medium renal failure rabbits (i.e., 0.027 h(-1)) than that in normal rabbits (i.e., 0.044 h(-1)); As a result, the terminal half-life of tolbutamide in medium folate-induced renal failure rabbits (i.e., 25.5 h) was significantly longer (p<0.01) than that in normal rabbits (i.e., 15.7 h).",Pharmacokinetics of tolbutamide after oral administration to rabbits with folate-induced renal failure. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14661866/),1/[h],0.044,33256,DB01124,Tolbutamide
,14661866,terminal half-life,"The elimination rate constant (Kel) of tolbutamide was significantly decreased in medium renal failure rabbits (i.e., 0.027 h(-1)) than that in normal rabbits (i.e., 0.044 h(-1)); As a result, the terminal half-life of tolbutamide in medium folate-induced renal failure rabbits (i.e., 25.5 h) was significantly longer (p<0.01) than that in normal rabbits (i.e., 15.7 h).",Pharmacokinetics of tolbutamide after oral administration to rabbits with folate-induced renal failure. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14661866/),h,25.5,33257,DB01124,Tolbutamide
,14661866,terminal half-life,"The elimination rate constant (Kel) of tolbutamide was significantly decreased in medium renal failure rabbits (i.e., 0.027 h(-1)) than that in normal rabbits (i.e., 0.044 h(-1)); As a result, the terminal half-life of tolbutamide in medium folate-induced renal failure rabbits (i.e., 25.5 h) was significantly longer (p<0.01) than that in normal rabbits (i.e., 15.7 h).",Pharmacokinetics of tolbutamide after oral administration to rabbits with folate-induced renal failure. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14661866/),h,15.7,33258,DB01124,Tolbutamide
,27451018,flow rate,Chromatographic separation was performed on an Atlantis dC18 column using a binary gradient using mobile phase A (acetonitrile) and B (0.2% formic acid in water) at a flow rate of 0.90 mL/min.,"Determination of epacadostat, a novel IDO1 inhibitor in mouse plasma by LC-MS/MS and its application to a pharmacokinetic study in mice. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27451018/),[ml] / [min],0.90,33339,DB01124,Tolbutamide
,27451018,total chromatographic run time,The total chromatographic run time was 3.2 min.,"Determination of epacadostat, a novel IDO1 inhibitor in mouse plasma by LC-MS/MS and its application to a pharmacokinetic study in mice. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27451018/),min,3.2,33340,DB01124,Tolbutamide
,32285669,area under the time-concentration curves,"The observed area under the time-concentration curves were unaffected, except for alprazolam which decreased 7.6% (564.6 ± 46.1 h·μg/L pre-hop and 521.9 ± 36.1 h·μg/L post-hop; p-value 0.047), suggesting minor induction of CYP3A4/5.",Pharmacokinetic Interactions of a Hop Dietary Supplement with Drug Metabolism in Perimenopausal and Postmenopausal Women. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32285669/),[h·μg] / [l],564.6,35551,DB01124,Tolbutamide
,32285669,area under the time-concentration curves,"The observed area under the time-concentration curves were unaffected, except for alprazolam which decreased 7.6% (564.6 ± 46.1 h·μg/L pre-hop and 521.9 ± 36.1 h·μg/L post-hop; p-value 0.047), suggesting minor induction of CYP3A4/5.",Pharmacokinetic Interactions of a Hop Dietary Supplement with Drug Metabolism in Perimenopausal and Postmenopausal Women. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32285669/),[h·μg] / [l],521.9,35552,DB01124,Tolbutamide
,3443146,total plasma clearance,"The mean values for total plasma clearance, elimination half-life, and metabolic clearance were 0.26 ml.min-1.kg-1, 3.4 h, and 0.17 ml.min-1.",Lack of relationship between tolbutamide metabolism and debrisoquine oxidation phenotype. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3443146/),[ml] / [kg·min],0.26,37598,DB01124,Tolbutamide
,3443146,elimination half-life,"The mean values for total plasma clearance, elimination half-life, and metabolic clearance were 0.26 ml.min-1.kg-1, 3.4 h, and 0.17 ml.min-1.",Lack of relationship between tolbutamide metabolism and debrisoquine oxidation phenotype. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3443146/),h,3.4,37599,DB01124,Tolbutamide
,3443146,metabolic clearance,"The mean values for total plasma clearance, elimination half-life, and metabolic clearance were 0.26 ml.min-1.kg-1, 3.4 h, and 0.17 ml.min-1.",Lack of relationship between tolbutamide metabolism and debrisoquine oxidation phenotype. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3443146/),[ml] / [min],0.17,37600,DB01124,Tolbutamide
,3443146,Total urinary recovery,Total urinary recovery (% of dose) and ratio of hydroxy- to carboxytolbutamide were 69.4% and 0.219 respectively in PM subjects and 70.9% and 0.226 in EM subjects.,Lack of relationship between tolbutamide metabolism and debrisoquine oxidation phenotype. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3443146/),%,69,37601,DB01124,Tolbutamide
,3443146,Total urinary recovery,Total urinary recovery (% of dose) and ratio of hydroxy- to carboxytolbutamide were 69.4% and 0.219 respectively in PM subjects and 70.9% and 0.226 in EM subjects.,Lack of relationship between tolbutamide metabolism and debrisoquine oxidation phenotype. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3443146/),%,70,37602,DB01124,Tolbutamide
,11740344,elimination half-life,She exhibited extremely poor clearance of phenytoin with an elimination half-life of approximately 13 days.,Identification of a null allele of CYP2C9 in an African-American exhibiting toxicity to phenytoin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11740344/),d,13,42025,DB01124,Tolbutamide
,25030991,flow-rate,"The chromatographic separation was performed on an Acquity UPLC BEH C18 column (2.1 × 50 mm, 1.7 μm particle size), using acetonitrile-0.1% formic acid as the mobile phase with gradient elution, delivered at a flow-rate of 0.4 mL/min.",Determination of rutin in rat plasma by ultra performance liquid chromatography tandem mass spectrometry and application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25030991/),[ml] / [min],0.4,44003,DB01124,Tolbutamide
,25030991,m/z,"The MRM transitions of m/z 610.91→302.98 and m/z 271.2→155.1 were used to quantify for rutin and tolbutamide, respectively.",Determination of rutin in rat plasma by ultra performance liquid chromatography tandem mass spectrometry and application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25030991/),,610.91,44004,DB01124,Tolbutamide
,25030991,m/z,"The MRM transitions of m/z 610.91→302.98 and m/z 271.2→155.1 were used to quantify for rutin and tolbutamide, respectively.",Determination of rutin in rat plasma by ultra performance liquid chromatography tandem mass spectrometry and application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25030991/),,302.98,44005,DB01124,Tolbutamide
,25030991,m/z,"The MRM transitions of m/z 610.91→302.98 and m/z 271.2→155.1 were used to quantify for rutin and tolbutamide, respectively.",Determination of rutin in rat plasma by ultra performance liquid chromatography tandem mass spectrometry and application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25030991/),,271.2,44006,DB01124,Tolbutamide
,25030991,m/z,"The MRM transitions of m/z 610.91→302.98 and m/z 271.2→155.1 were used to quantify for rutin and tolbutamide, respectively.",Determination of rutin in rat plasma by ultra performance liquid chromatography tandem mass spectrometry and application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25030991/),,155.1,44007,DB01124,Tolbutamide
,11180037,total clearance,"During treatment with fluvoxamine, there was a statistically significant decrease in the median of the total clearance of tolbutamide, from 845 mL/h to 688 mL/h, among the volunteers who received 75 mg/d.",Fluvoxamine inhibits the CYP2C9 catalyzed biotransformation of tolbutamide. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11180037/),[ml] / [h],845,48724,DB01124,Tolbutamide
,11180037,total clearance,"During treatment with fluvoxamine, there was a statistically significant decrease in the median of the total clearance of tolbutamide, from 845 mL/h to 688 mL/h, among the volunteers who received 75 mg/d.",Fluvoxamine inhibits the CYP2C9 catalyzed biotransformation of tolbutamide. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11180037/),[ml] / [h],688,48725,DB01124,Tolbutamide
,11180037,clearance,"The clearance by means of 4-hydroxytolbutamide and carboxytolbutamide was significantly reduced in both groups (ie, from 901 mL/h to 318 mL/h in the group that received 150 mg of tolbutamide per day and from 723 mL/h to 457 mL/h in the group that received 75 mg of tolbutamide per day).",Fluvoxamine inhibits the CYP2C9 catalyzed biotransformation of tolbutamide. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11180037/),[ml] / [h],901,48726,DB01124,Tolbutamide
,11180037,clearance,"The clearance by means of 4-hydroxytolbutamide and carboxytolbutamide was significantly reduced in both groups (ie, from 901 mL/h to 318 mL/h in the group that received 150 mg of tolbutamide per day and from 723 mL/h to 457 mL/h in the group that received 75 mg of tolbutamide per day).",Fluvoxamine inhibits the CYP2C9 catalyzed biotransformation of tolbutamide. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11180037/),[ml] / [h],318,48727,DB01124,Tolbutamide
,11180037,clearance,"The clearance by means of 4-hydroxytolbutamide and carboxytolbutamide was significantly reduced in both groups (ie, from 901 mL/h to 318 mL/h in the group that received 150 mg of tolbutamide per day and from 723 mL/h to 457 mL/h in the group that received 75 mg of tolbutamide per day).",Fluvoxamine inhibits the CYP2C9 catalyzed biotransformation of tolbutamide. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11180037/),[ml] / [h],723,48728,DB01124,Tolbutamide
,11180037,clearance,"The clearance by means of 4-hydroxytolbutamide and carboxytolbutamide was significantly reduced in both groups (ie, from 901 mL/h to 318 mL/h in the group that received 150 mg of tolbutamide per day and from 723 mL/h to 457 mL/h in the group that received 75 mg of tolbutamide per day).",Fluvoxamine inhibits the CYP2C9 catalyzed biotransformation of tolbutamide. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11180037/),[ml] / [h],457,48729,DB01124,Tolbutamide
,3169118,Control half-life,Control half-life of tolbutamide 6.29 h was not significantly altered by cimetidine (6.93 h) or ranitidine (6.97 h).,Lack of efficacy of cimetidine and ranitidine as inhibitors of tolbutamide metabolism. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3169118/),h,6.29,51051,DB01124,Tolbutamide
,3169118,Control half-life,Control half-life of tolbutamide 6.29 h was not significantly altered by cimetidine (6.93 h) or ranitidine (6.97 h).,Lack of efficacy of cimetidine and ranitidine as inhibitors of tolbutamide metabolism. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3169118/),h,6.93,51052,DB01124,Tolbutamide
,3169118,Control half-life,Control half-life of tolbutamide 6.29 h was not significantly altered by cimetidine (6.93 h) or ranitidine (6.97 h).,Lack of efficacy of cimetidine and ranitidine as inhibitors of tolbutamide metabolism. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3169118/),h,6.97,51053,DB01124,Tolbutamide
,3169118,apparent oral clearance,"The corresponding apparent oral clearance (ml.min-1.kg-1) were not significantly different: 0.26 (control), 0.24 (cimetidine) and 0.25 (ranitidine).",Lack of efficacy of cimetidine and ranitidine as inhibitors of tolbutamide metabolism. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3169118/),[ml] / [kg·min],0.26,51054,DB01124,Tolbutamide
,3169118,apparent oral clearance,"The corresponding apparent oral clearance (ml.min-1.kg-1) were not significantly different: 0.26 (control), 0.24 (cimetidine) and 0.25 (ranitidine).",Lack of efficacy of cimetidine and ranitidine as inhibitors of tolbutamide metabolism. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3169118/),[ml] / [kg·min],0.24,51055,DB01124,Tolbutamide
,3169118,apparent oral clearance,"The corresponding apparent oral clearance (ml.min-1.kg-1) were not significantly different: 0.26 (control), 0.24 (cimetidine) and 0.25 (ranitidine).",Lack of efficacy of cimetidine and ranitidine as inhibitors of tolbutamide metabolism. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3169118/),[ml] / [kg·min],0.25,51056,DB01124,Tolbutamide
,3169118,Apparent volume of distribution,"Apparent volume of distribution was also unaltered 0.140 l.kg-1 (control), 0.141 l.kg-1 (cimetidine) and 0.146 l.kg-1 (ranitidine).",Lack of efficacy of cimetidine and ranitidine as inhibitors of tolbutamide metabolism. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3169118/),[l] / [kg],0.140,51057,DB01124,Tolbutamide
,3169118,Apparent volume of distribution,"Apparent volume of distribution was also unaltered 0.140 l.kg-1 (control), 0.141 l.kg-1 (cimetidine) and 0.146 l.kg-1 (ranitidine).",Lack of efficacy of cimetidine and ranitidine as inhibitors of tolbutamide metabolism. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3169118/),[l] / [kg],0.141,51058,DB01124,Tolbutamide
,3169118,Apparent volume of distribution,"Apparent volume of distribution was also unaltered 0.140 l.kg-1 (control), 0.141 l.kg-1 (cimetidine) and 0.146 l.kg-1 (ranitidine).",Lack of efficacy of cimetidine and ranitidine as inhibitors of tolbutamide metabolism. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3169118/),[l] / [kg],0.146,51059,DB01124,Tolbutamide
,32116727,IC50,"In vitro analysis revealed that the IC50 values of midazolam, tolbutamide, dextromethorphan, and bupropion in rat microsomes were 22.48, 18.34, 3.62, and 3.68 μM, respectively, while chlorzoxazone and phenacetin displayed no inhibition.",Cytochrome P450-Based Drug-Drug Interactions of Vonoprazan In Vitro and In Vivo. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32116727/),μM,22.48,65057,DB01124,Tolbutamide
,32116727,IC50,"In vitro analysis revealed that the IC50 values of midazolam, tolbutamide, dextromethorphan, and bupropion in rat microsomes were 22.48, 18.34, 3.62, and 3.68 μM, respectively, while chlorzoxazone and phenacetin displayed no inhibition.",Cytochrome P450-Based Drug-Drug Interactions of Vonoprazan In Vitro and In Vivo. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32116727/),μM,18.34,65058,DB01124,Tolbutamide
,32116727,IC50,"In vitro analysis revealed that the IC50 values of midazolam, tolbutamide, dextromethorphan, and bupropion in rat microsomes were 22.48, 18.34, 3.62, and 3.68 μM, respectively, while chlorzoxazone and phenacetin displayed no inhibition.",Cytochrome P450-Based Drug-Drug Interactions of Vonoprazan In Vitro and In Vivo. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32116727/),μM,3.62,65059,DB01124,Tolbutamide
,32116727,IC50,"In vitro analysis revealed that the IC50 values of midazolam, tolbutamide, dextromethorphan, and bupropion in rat microsomes were 22.48, 18.34, 3.62, and 3.68 μM, respectively, while chlorzoxazone and phenacetin displayed no inhibition.",Cytochrome P450-Based Drug-Drug Interactions of Vonoprazan In Vitro and In Vivo. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32116727/),μM,3.68,65060,DB01124,Tolbutamide
,30117207,recovery,LKE showed good recovery ranging from 77-90% in serum and 82-88% in brain tissue.,"Analysis of lanthionine ketimine ethyl ester in mouse serum, whole blood and tissues using ultrahigh-pressure liquid chromatography/tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30117207/),%,77-90,65782,DB01124,Tolbutamide
,30117207,recovery,LKE showed good recovery ranging from 77-90% in serum and 82-88% in brain tissue.,"Analysis of lanthionine ketimine ethyl ester in mouse serum, whole blood and tissues using ultrahigh-pressure liquid chromatography/tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30117207/),%,82-88,65783,DB01124,Tolbutamide
,30117207,LKE,"The average LKE detected in mouse serum was 277.42 nM, while the concentration in whole blood was 38 nM.","Analysis of lanthionine ketimine ethyl ester in mouse serum, whole blood and tissues using ultrahigh-pressure liquid chromatography/tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30117207/),nM,277.42,65784,DB01124,Tolbutamide
,30117207,LKE,"The average LKE detected in mouse serum was 277.42 nM, while the concentration in whole blood was 38 nM.","Analysis of lanthionine ketimine ethyl ester in mouse serum, whole blood and tissues using ultrahigh-pressure liquid chromatography/tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30117207/),n,38,65785,DB01124,Tolbutamide
,9117089,Ki,"The Ki value was 4.34 +/- 0.04 x 10(7) M, and the displacement potency of A-4166 was between that of glibenclamide and tolbutamide, being similar to that of gliclazide.","Hypoglycaemic and insulinotropic effects of a novel oral antidiabetic agent, (-)-N-(trans-4-isopropylcyclohexanecarbonyl)-D-phenylalanine (A-4166). ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9117089/),M,4.34,68040,DB01124,Tolbutamide
,28284082,m/z,"The ion transitions of the precursor to the product ion were principally protonated ions [M+H]+ at m/z 446.4→m/z 321.1 for glipizide, m/z 462.2→m/z 321.1 for the four hydroxylated forms of glipizide, m/z 287.2→m/z 188.0 for 4'-OH-tolbutamide, and m/z 324.1→m/z 127.1 for gliclazide.",Simultaneous determination of glipizide and its four hydroxylated metabolites in human urine using LC-MS/MS and its application in urinary phenotype study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28284082/),→,287.2,73622,DB01124,Tolbutamide
,28284082,m/z,"The ion transitions of the precursor to the product ion were principally protonated ions [M+H]+ at m/z 446.4→m/z 321.1 for glipizide, m/z 462.2→m/z 321.1 for the four hydroxylated forms of glipizide, m/z 287.2→m/z 188.0 for 4'-OH-tolbutamide, and m/z 324.1→m/z 127.1 for gliclazide.",Simultaneous determination of glipizide and its four hydroxylated metabolites in human urine using LC-MS/MS and its application in urinary phenotype study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28284082/),,188.0,73623,DB01124,Tolbutamide
,28284082,m,"The ion transitions of the precursor to the product ion were principally protonated ions [M+H]+ at m/z 446.4→m/z 321.1 for glipizide, m/z 462.2→m/z 321.1 for the four hydroxylated forms of glipizide, m/z 287.2→m/z 188.0 for 4'-OH-tolbutamide, and m/z 324.1→m/z 127.1 for gliclazide.",Simultaneous determination of glipizide and its four hydroxylated metabolites in human urine using LC-MS/MS and its application in urinary phenotype study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28284082/),→,324.1,73624,DB01124,Tolbutamide
,32272615,IC50 (Ki),"Of the nine tested CYPs, it exerted the strongest inhibitory effect on CYP2C9-mediated tolbutamide 4-hydroxylation with the lowest IC50 (Ki) value of 0.966 ± 0.149 μM (0.503 ± 0.0383 μM), in a competitive manner.",Lack of Correlation between In Vitro and In Vivo Studies on the Inhibitory Effects of (‒)-Sophoranone on CYP2C9 is Attributable to Low Oral Absorption and Extensive Plasma Protein Binding of (‒)-Sophoranone. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32272615/),μM,0.966,82028,DB01124,Tolbutamide
,32272615,IC50 (Ki),"Of the nine tested CYPs, it exerted the strongest inhibitory effect on CYP2C9-mediated tolbutamide 4-hydroxylation with the lowest IC50 (Ki) value of 0.966 ± 0.149 μM (0.503 ± 0.0383 μM), in a competitive manner.",Lack of Correlation between In Vitro and In Vivo Studies on the Inhibitory Effects of (‒)-Sophoranone on CYP2C9 is Attributable to Low Oral Absorption and Extensive Plasma Protein Binding of (‒)-Sophoranone. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32272615/),μM,0.503,82029,DB01124,Tolbutamide
,32272615,Papp,"The very low permeability of SPN in Caco-2 cells (Papp value of 0.115 × 10-6 cm/s), which suggests poor absorption in vivo, and its high degree of plasma protein binding (>99.9%) may lead to the lack of in vitro-in vivo correlation.",Lack of Correlation between In Vitro and In Vivo Studies on the Inhibitory Effects of (‒)-Sophoranone on CYP2C9 is Attributable to Low Oral Absorption and Extensive Plasma Protein Binding of (‒)-Sophoranone. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32272615/),[cm] / [s],0.115 × 10-6,82030,DB01124,Tolbutamide
>,32272615,plasma protein binding,"The very low permeability of SPN in Caco-2 cells (Papp value of 0.115 × 10-6 cm/s), which suggests poor absorption in vivo, and its high degree of plasma protein binding (>99.9%) may lead to the lack of in vitro-in vivo correlation.",Lack of Correlation between In Vitro and In Vivo Studies on the Inhibitory Effects of (‒)-Sophoranone on CYP2C9 is Attributable to Low Oral Absorption and Extensive Plasma Protein Binding of (‒)-Sophoranone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32272615/),%,99.9,82031,DB01124,Tolbutamide
,15244039,area under the plasma concentration-time curves (AUC),"Therefore, the area under the plasma concentration-time curves (AUC) was significantly higher (p<0.05 and p<0.01 respectively) in mild and medium folate-induced renal failure rabbits (2906 microg/ml x hr and 4074 microg/ml x hr) than that in normal rabbits (2295 microg/ml x hr).",Pharmacokinetics of tolbutamide after oral administration in rabbits with folate-induced renal failure. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15244039/),[μg] / [h·ml],2906,83422,DB01124,Tolbutamide
,15244039,area under the plasma concentration-time curves (AUC),"Therefore, the area under the plasma concentration-time curves (AUC) was significantly higher (p<0.05 and p<0.01 respectively) in mild and medium folate-induced renal failure rabbits (2906 microg/ml x hr and 4074 microg/ml x hr) than that in normal rabbits (2295 microg/ml x hr).",Pharmacokinetics of tolbutamide after oral administration in rabbits with folate-induced renal failure. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15244039/),[μg] / [h·ml],4074,83423,DB01124,Tolbutamide
,15244039,area under the plasma concentration-time curves (AUC),"Therefore, the area under the plasma concentration-time curves (AUC) was significantly higher (p<0.05 and p<0.01 respectively) in mild and medium folate-induced renal failure rabbits (2906 microg/ml x hr and 4074 microg/ml x hr) than that in normal rabbits (2295 microg/ml x hr).",Pharmacokinetics of tolbutamide after oral administration in rabbits with folate-induced renal failure. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15244039/),[μg] / [h·ml],2295,83424,DB01124,Tolbutamide
,15244039,elimination rate constant (Kel),The elimination rate constant (Kel) of tolbutamide was significantly slower in medium folate-induced renal failure rabbits (0.027 hr(-1)) than that in normal rabbits(0.044 hr(-1)).,Pharmacokinetics of tolbutamide after oral administration in rabbits with folate-induced renal failure. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15244039/),1/[hr],0.027,83425,DB01124,Tolbutamide
,15244039,elimination rate constant (Kel),The elimination rate constant (Kel) of tolbutamide was significantly slower in medium folate-induced renal failure rabbits (0.027 hr(-1)) than that in normal rabbits(0.044 hr(-1)).,Pharmacokinetics of tolbutamide after oral administration in rabbits with folate-induced renal failure. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15244039/),1/[hr],0.044,83426,DB01124,Tolbutamide
,15244039,terminal half-life,The terminal half-life of tolbutamide in medium folate-induced renal failure rabbits (25.5 hr) was significantly longer (p<0.01) than in normal rabbits (15.7 hr).,Pharmacokinetics of tolbutamide after oral administration in rabbits with folate-induced renal failure. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15244039/),h,25.5,83427,DB01124,Tolbutamide
,15244039,terminal half-life,The terminal half-life of tolbutamide in medium folate-induced renal failure rabbits (25.5 hr) was significantly longer (p<0.01) than in normal rabbits (15.7 hr).,Pharmacokinetics of tolbutamide after oral administration in rabbits with folate-induced renal failure. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15244039/),h,15.7,83428,DB01124,Tolbutamide
,1139863,half-life (T/2),"In 8 patients DPH means half-life (T/2) increased from 11.8 plus or minus 3.6 hr to 19.6 plus or minus 5.2 hr and mean metabolic clearance rate (MCR) decreased from 43.7 plus or minus 16,8 to 28.1 plus or minus 9.1 ml/min durus or minus 1.2 to 9.2 plus or minus 1.2 hr MCR decrease from 17.0 plus or minus 5.4 to 10.5 plus or minus 1.2 ml/min.","Sulfamethizole-induced inhibition of diphenlhydantoin, tolbutamide, and warfarin metabolism. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1139863/),h,11.8,85544,DB01124,Tolbutamide
,1139863,half-life (T/2),"In 8 patients DPH means half-life (T/2) increased from 11.8 plus or minus 3.6 hr to 19.6 plus or minus 5.2 hr and mean metabolic clearance rate (MCR) decreased from 43.7 plus or minus 16,8 to 28.1 plus or minus 9.1 ml/min durus or minus 1.2 to 9.2 plus or minus 1.2 hr MCR decrease from 17.0 plus or minus 5.4 to 10.5 plus or minus 1.2 ml/min.","Sulfamethizole-induced inhibition of diphenlhydantoin, tolbutamide, and warfarin metabolism. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1139863/),h,19.6,85545,DB01124,Tolbutamide
,1139863,metabolic clearance rate (MCR),"In 8 patients DPH means half-life (T/2) increased from 11.8 plus or minus 3.6 hr to 19.6 plus or minus 5.2 hr and mean metabolic clearance rate (MCR) decreased from 43.7 plus or minus 16,8 to 28.1 plus or minus 9.1 ml/min durus or minus 1.2 to 9.2 plus or minus 1.2 hr MCR decrease from 17.0 plus or minus 5.4 to 10.5 plus or minus 1.2 ml/min.","Sulfamethizole-induced inhibition of diphenlhydantoin, tolbutamide, and warfarin metabolism. ",CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1139863/),[ml] / [min],43.7,85546,DB01124,Tolbutamide
,1139863,metabolic clearance rate (MCR),"In 8 patients DPH means half-life (T/2) increased from 11.8 plus or minus 3.6 hr to 19.6 plus or minus 5.2 hr and mean metabolic clearance rate (MCR) decreased from 43.7 plus or minus 16,8 to 28.1 plus or minus 9.1 ml/min durus or minus 1.2 to 9.2 plus or minus 1.2 hr MCR decrease from 17.0 plus or minus 5.4 to 10.5 plus or minus 1.2 ml/min.","Sulfamethizole-induced inhibition of diphenlhydantoin, tolbutamide, and warfarin metabolism. ",CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1139863/),[ml] / [min],28.1,85547,DB01124,Tolbutamide
,1139863,metabolic clearance rate (MCR),"In 8 patients DPH means half-life (T/2) increased from 11.8 plus or minus 3.6 hr to 19.6 plus or minus 5.2 hr and mean metabolic clearance rate (MCR) decreased from 43.7 plus or minus 16,8 to 28.1 plus or minus 9.1 ml/min durus or minus 1.2 to 9.2 plus or minus 1.2 hr MCR decrease from 17.0 plus or minus 5.4 to 10.5 plus or minus 1.2 ml/min.","Sulfamethizole-induced inhibition of diphenlhydantoin, tolbutamide, and warfarin metabolism. ",CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1139863/),h,9.2,85548,DB01124,Tolbutamide
,1139863,MCR,"In 8 patients DPH means half-life (T/2) increased from 11.8 plus or minus 3.6 hr to 19.6 plus or minus 5.2 hr and mean metabolic clearance rate (MCR) decreased from 43.7 plus or minus 16,8 to 28.1 plus or minus 9.1 ml/min durus or minus 1.2 to 9.2 plus or minus 1.2 hr MCR decrease from 17.0 plus or minus 5.4 to 10.5 plus or minus 1.2 ml/min.","Sulfamethizole-induced inhibition of diphenlhydantoin, tolbutamide, and warfarin metabolism. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1139863/),[ml] / [min],17.0,85549,DB01124,Tolbutamide
,1139863,MCR,"In 8 patients DPH means half-life (T/2) increased from 11.8 plus or minus 3.6 hr to 19.6 plus or minus 5.2 hr and mean metabolic clearance rate (MCR) decreased from 43.7 plus or minus 16,8 to 28.1 plus or minus 9.1 ml/min durus or minus 1.2 to 9.2 plus or minus 1.2 hr MCR decrease from 17.0 plus or minus 5.4 to 10.5 plus or minus 1.2 ml/min.","Sulfamethizole-induced inhibition of diphenlhydantoin, tolbutamide, and warfarin metabolism. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1139863/),[ml] / [min],10.5,85550,DB01124,Tolbutamide
,1139863,T/2,In 2 patients warfarin T/2 increased fron an average of 64.7 to 92.7 hr and MCR decreased from 1.65 ml/min to 1.05 ml/min.,"Sulfamethizole-induced inhibition of diphenlhydantoin, tolbutamide, and warfarin metabolism. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1139863/),h,64.7 to 92.7,85551,DB01124,Tolbutamide
,1139863,MCR,In 2 patients warfarin T/2 increased fron an average of 64.7 to 92.7 hr and MCR decreased from 1.65 ml/min to 1.05 ml/min.,"Sulfamethizole-induced inhibition of diphenlhydantoin, tolbutamide, and warfarin metabolism. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1139863/),[ml] / [min],1.65,85552,DB01124,Tolbutamide
,1139863,MCR,In 2 patients warfarin T/2 increased fron an average of 64.7 to 92.7 hr and MCR decreased from 1.65 ml/min to 1.05 ml/min.,"Sulfamethizole-induced inhibition of diphenlhydantoin, tolbutamide, and warfarin metabolism. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1139863/),[ml] / [min],1.05,85553,DB01124,Tolbutamide
,11854150,intrinsic clearance per,"For the different incubations, the intrinsic clearance per unit of volume of slice ranged from 0.035 to 0.086 min(-1) when not correcting for slice viability and from 0.044 to 0.11 min(-1) when correcting for slice viability.","Utility of rat liver slices to estimate hepatic clearance for application in physiologically based pharmacokinetic modeling: a study with tolbutamide, a compound with low extraction efficiency. ",CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11854150/),1/[min],0.035 to 0.086,87037,DB01124,Tolbutamide
,11854150,intrinsic clearance per,"For the different incubations, the intrinsic clearance per unit of volume of slice ranged from 0.035 to 0.086 min(-1) when not correcting for slice viability and from 0.044 to 0.11 min(-1) when correcting for slice viability.","Utility of rat liver slices to estimate hepatic clearance for application in physiologically based pharmacokinetic modeling: a study with tolbutamide, a compound with low extraction efficiency. ",CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11854150/),1/[min],0.044 to 0.11,87038,DB01124,Tolbutamide
,11854150,intrinsic clearance,The value for the intrinsic clearance found by calibrating the PBPK model to previous in vivo data was 0.090 min(-1).,"Utility of rat liver slices to estimate hepatic clearance for application in physiologically based pharmacokinetic modeling: a study with tolbutamide, a compound with low extraction efficiency. ",CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11854150/),1/[min],0.090,87039,DB01124,Tolbutamide
,837649,volume of distribution,"Although during the acute phase of illness protein binding of the drug decreased in all, volume of distribution of tolbutamide (0.15 +/- 0.03 L/kg) did not change.",Influence of acute viral hepatitis on disposition and plasma binding of tolbutamide. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/837649/),[l] / [kg],0.15,88137,DB01124,Tolbutamide
,837649,Clearance,"Clearance based on total concentration of tolbutamide in plasma increased in all subjects during the acute phase of study (26 +/- 5.4 ml/hr/kg) in comparison to the recovery phase (18 +/- 2.8 ml/hr/kg, p less than 0.02).",Influence of acute viral hepatitis on disposition and plasma binding of tolbutamide. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/837649/),[ml] / [h·kg],26,88138,DB01124,Tolbutamide
,837649,Clearance,"Clearance based on total concentration of tolbutamide in plasma increased in all subjects during the acute phase of study (26 +/- 5.4 ml/hr/kg) in comparison to the recovery phase (18 +/- 2.8 ml/hr/kg, p less than 0.02).",Influence of acute viral hepatitis on disposition and plasma binding of tolbutamide. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/837649/),[ml] / [h·kg],18,88139,DB01124,Tolbutamide
,837649,Clearance based on unbound drug concentration,"Clearance based on unbound drug concentration, calculated by dividing the observed plasma clearance by the fraction of unbound drug in plasma, did not differ significantly between the 2 study phases (300 +/- 47 and 260 +/- 39 ml/hr/kg).",Influence of acute viral hepatitis on disposition and plasma binding of tolbutamide. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/837649/),[ml] / [h·kg],300,88140,DB01124,Tolbutamide
,837649,Clearance based on unbound drug concentration,"Clearance based on unbound drug concentration, calculated by dividing the observed plasma clearance by the fraction of unbound drug in plasma, did not differ significantly between the 2 study phases (300 +/- 47 and 260 +/- 39 ml/hr/kg).",Influence of acute viral hepatitis on disposition and plasma binding of tolbutamide. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/837649/),[ml] / [h·kg],260,88141,DB01124,Tolbutamide
,837649,plasma clearance,"Clearance based on unbound drug concentration, calculated by dividing the observed plasma clearance by the fraction of unbound drug in plasma, did not differ significantly between the 2 study phases (300 +/- 47 and 260 +/- 39 ml/hr/kg).",Influence of acute viral hepatitis on disposition and plasma binding of tolbutamide. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/837649/),[ml] / [h·kg],300,88142,DB01124,Tolbutamide
,837649,plasma clearance,"Clearance based on unbound drug concentration, calculated by dividing the observed plasma clearance by the fraction of unbound drug in plasma, did not differ significantly between the 2 study phases (300 +/- 47 and 260 +/- 39 ml/hr/kg).",Influence of acute viral hepatitis on disposition and plasma binding of tolbutamide. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/837649/),[ml] / [h·kg],260,88143,DB01124,Tolbutamide
,28383683,flow rate,"Chromatographic separation was performed on an Atlantis dC18 column using an isocratic mobile phase comprising 0.2% formic acid:acetonitrile (10:90, v/v) at a flow rate of 0.60 mL/min.",Validated LC-MS-MS Method for Determination of SF0034 in Mice Plasma: Application to a Pharmacokinetic Study in Mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28383683/),[ml] / [min],0.60,92260,DB01124,Tolbutamide
,28383683,total run time,The total run time was 2.5 min.,Validated LC-MS-MS Method for Determination of SF0034 in Mice Plasma: Application to a Pharmacokinetic Study in Mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28383683/),min,2.5,92261,DB01124,Tolbutamide
,28383683,m/,"For mass spectrometric detection, the multiple reaction monitoring was used and ion transitions monitored were m/z 322 → 248 for SF0034 and 271 → 155 for IS.",Validated LC-MS-MS Method for Determination of SF0034 in Mice Plasma: Application to a Pharmacokinetic Study in Mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28383683/),,322,92262,DB01124,Tolbutamide
,28383683,m/,"For mass spectrometric detection, the multiple reaction monitoring was used and ion transitions monitored were m/z 322 → 248 for SF0034 and 271 → 155 for IS.",Validated LC-MS-MS Method for Determination of SF0034 in Mice Plasma: Application to a Pharmacokinetic Study in Mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28383683/),,248,92263,DB01124,Tolbutamide
,11875364,oral clearances,"The mean oral clearances of tolbutamide were 0.97 (95% confidence interval [CI] 0.89-1.05), 0.86 (95% CI 0.79-0.93), 0.75 (95% CI 0.69-0.81), 0.56 (95% CI 0.51-0.61), 0.45 (95% CI 0.41-0.49) and 0.15 (95% CI 0.14-0.16) l/h in carriers of CYP2C9 genotypes 1/*1, *1/*2, *2/*2, *1/*3, *2/*3 and *3/*3, respectively.",Impact of CYP2C9 and CYP2C19 polymorphisms on tolbutamide kinetics and the insulin and glucose response in healthy volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11875364/),[l] / [h],0.97,93783,DB01124,Tolbutamide
,11875364,oral clearances,"The mean oral clearances of tolbutamide were 0.97 (95% confidence interval [CI] 0.89-1.05), 0.86 (95% CI 0.79-0.93), 0.75 (95% CI 0.69-0.81), 0.56 (95% CI 0.51-0.61), 0.45 (95% CI 0.41-0.49) and 0.15 (95% CI 0.14-0.16) l/h in carriers of CYP2C9 genotypes 1/*1, *1/*2, *2/*2, *1/*3, *2/*3 and *3/*3, respectively.",Impact of CYP2C9 and CYP2C19 polymorphisms on tolbutamide kinetics and the insulin and glucose response in healthy volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11875364/),[l] / [h],0.86,93784,DB01124,Tolbutamide
,11875364,oral clearances,"The mean oral clearances of tolbutamide were 0.97 (95% confidence interval [CI] 0.89-1.05), 0.86 (95% CI 0.79-0.93), 0.75 (95% CI 0.69-0.81), 0.56 (95% CI 0.51-0.61), 0.45 (95% CI 0.41-0.49) and 0.15 (95% CI 0.14-0.16) l/h in carriers of CYP2C9 genotypes 1/*1, *1/*2, *2/*2, *1/*3, *2/*3 and *3/*3, respectively.",Impact of CYP2C9 and CYP2C19 polymorphisms on tolbutamide kinetics and the insulin and glucose response in healthy volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11875364/),[l] / [h],0.75,93785,DB01124,Tolbutamide
,11875364,oral clearances,"The mean oral clearances of tolbutamide were 0.97 (95% confidence interval [CI] 0.89-1.05), 0.86 (95% CI 0.79-0.93), 0.75 (95% CI 0.69-0.81), 0.56 (95% CI 0.51-0.61), 0.45 (95% CI 0.41-0.49) and 0.15 (95% CI 0.14-0.16) l/h in carriers of CYP2C9 genotypes 1/*1, *1/*2, *2/*2, *1/*3, *2/*3 and *3/*3, respectively.",Impact of CYP2C9 and CYP2C19 polymorphisms on tolbutamide kinetics and the insulin and glucose response in healthy volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11875364/),[l] / [h],0.56,93786,DB01124,Tolbutamide
,11875364,oral clearances,"The mean oral clearances of tolbutamide were 0.97 (95% confidence interval [CI] 0.89-1.05), 0.86 (95% CI 0.79-0.93), 0.75 (95% CI 0.69-0.81), 0.56 (95% CI 0.51-0.61), 0.45 (95% CI 0.41-0.49) and 0.15 (95% CI 0.14-0.16) l/h in carriers of CYP2C9 genotypes 1/*1, *1/*2, *2/*2, *1/*3, *2/*3 and *3/*3, respectively.",Impact of CYP2C9 and CYP2C19 polymorphisms on tolbutamide kinetics and the insulin and glucose response in healthy volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11875364/),[l] / [h],0.45,93787,DB01124,Tolbutamide
,11875364,oral clearances,"The mean oral clearances of tolbutamide were 0.97 (95% confidence interval [CI] 0.89-1.05), 0.86 (95% CI 0.79-0.93), 0.75 (95% CI 0.69-0.81), 0.56 (95% CI 0.51-0.61), 0.45 (95% CI 0.41-0.49) and 0.15 (95% CI 0.14-0.16) l/h in carriers of CYP2C9 genotypes 1/*1, *1/*2, *2/*2, *1/*3, *2/*3 and *3/*3, respectively.",Impact of CYP2C9 and CYP2C19 polymorphisms on tolbutamide kinetics and the insulin and glucose response in healthy volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11875364/),[l] / [h],0.15,93788,DB01124,Tolbutamide
,9068933,terminal elimination half-life,"The terminal elimination rate constant was also significantly reduced, corresponding to the increase in the terminal elimination half-life (from 6.9 to 8.6 hours).",A study of the potential effect of sertraline on the pharmacokinetics and protein binding of tolbutamide. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9068933/),h,6.9,97926,DB01124,Tolbutamide
,9068933,terminal elimination half-life,"The terminal elimination rate constant was also significantly reduced, corresponding to the increase in the terminal elimination half-life (from 6.9 to 8.6 hours).",A study of the potential effect of sertraline on the pharmacokinetics and protein binding of tolbutamide. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9068933/),h,8.6,97927,DB01124,Tolbutamide
,23222033,time to maximum plasma concentration (tmax),"Compared with controls, the RYGB group had significantly lower time to maximum plasma concentration (tmax) for caffeine (0.58 ± 0.5 vs 2.1 ± 2.2 hours, P < 0.0001), tolbutamide (1.4 ± 1.8 vs 2.1 ± 2.2 hours, P = 0.0001), omeprazole (1.1 ± 1.1 vs 4.4 ± 1.3 hours, P < 0.0001), and oral midazolam (0.5 ± 0.2 vs 0.7 ± 0.4 hours, P < 0.01).",Pharmacokinetic and pharmacodynamic alterations in the Roux-en-Y gastric bypass recipients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23222033/),h,0.58,98193,DB01124,Tolbutamide
,23222033,time to maximum plasma concentration (tmax),"Compared with controls, the RYGB group had significantly lower time to maximum plasma concentration (tmax) for caffeine (0.58 ± 0.5 vs 2.1 ± 2.2 hours, P < 0.0001), tolbutamide (1.4 ± 1.8 vs 2.1 ± 2.2 hours, P = 0.0001), omeprazole (1.1 ± 1.1 vs 4.4 ± 1.3 hours, P < 0.0001), and oral midazolam (0.5 ± 0.2 vs 0.7 ± 0.4 hours, P < 0.01).",Pharmacokinetic and pharmacodynamic alterations in the Roux-en-Y gastric bypass recipients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23222033/),h,2.1,98194,DB01124,Tolbutamide
,23222033,time to maximum plasma concentration (tmax),"Compared with controls, the RYGB group had significantly lower time to maximum plasma concentration (tmax) for caffeine (0.58 ± 0.5 vs 2.1 ± 2.2 hours, P < 0.0001), tolbutamide (1.4 ± 1.8 vs 2.1 ± 2.2 hours, P = 0.0001), omeprazole (1.1 ± 1.1 vs 4.4 ± 1.3 hours, P < 0.0001), and oral midazolam (0.5 ± 0.2 vs 0.7 ± 0.4 hours, P < 0.01).",Pharmacokinetic and pharmacodynamic alterations in the Roux-en-Y gastric bypass recipients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23222033/),h,1.4,98195,DB01124,Tolbutamide
,23222033,time to maximum plasma concentration (tmax),"Compared with controls, the RYGB group had significantly lower time to maximum plasma concentration (tmax) for caffeine (0.58 ± 0.5 vs 2.1 ± 2.2 hours, P < 0.0001), tolbutamide (1.4 ± 1.8 vs 2.1 ± 2.2 hours, P = 0.0001), omeprazole (1.1 ± 1.1 vs 4.4 ± 1.3 hours, P < 0.0001), and oral midazolam (0.5 ± 0.2 vs 0.7 ± 0.4 hours, P < 0.01).",Pharmacokinetic and pharmacodynamic alterations in the Roux-en-Y gastric bypass recipients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23222033/),h,1.1,98196,DB01124,Tolbutamide
,23222033,time to maximum plasma concentration (tmax),"Compared with controls, the RYGB group had significantly lower time to maximum plasma concentration (tmax) for caffeine (0.58 ± 0.5 vs 2.1 ± 2.2 hours, P < 0.0001), tolbutamide (1.4 ± 1.8 vs 2.1 ± 2.2 hours, P = 0.0001), omeprazole (1.1 ± 1.1 vs 4.4 ± 1.3 hours, P < 0.0001), and oral midazolam (0.5 ± 0.2 vs 0.7 ± 0.4 hours, P < 0.01).",Pharmacokinetic and pharmacodynamic alterations in the Roux-en-Y gastric bypass recipients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23222033/),h,4.4,98197,DB01124,Tolbutamide
,23222033,time to maximum plasma concentration (tmax),"Compared with controls, the RYGB group had significantly lower time to maximum plasma concentration (tmax) for caffeine (0.58 ± 0.5 vs 2.1 ± 2.2 hours, P < 0.0001), tolbutamide (1.4 ± 1.8 vs 2.1 ± 2.2 hours, P = 0.0001), omeprazole (1.1 ± 1.1 vs 4.4 ± 1.3 hours, P < 0.0001), and oral midazolam (0.5 ± 0.2 vs 0.7 ± 0.4 hours, P < 0.01).",Pharmacokinetic and pharmacodynamic alterations in the Roux-en-Y gastric bypass recipients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23222033/),h,0.5,98198,DB01124,Tolbutamide
,23222033,time to maximum plasma concentration (tmax),"Compared with controls, the RYGB group had significantly lower time to maximum plasma concentration (tmax) for caffeine (0.58 ± 0.5 vs 2.1 ± 2.2 hours, P < 0.0001), tolbutamide (1.4 ± 1.8 vs 2.1 ± 2.2 hours, P = 0.0001), omeprazole (1.1 ± 1.1 vs 4.4 ± 1.3 hours, P < 0.0001), and oral midazolam (0.5 ± 0.2 vs 0.7 ± 0.4 hours, P < 0.01).",Pharmacokinetic and pharmacodynamic alterations in the Roux-en-Y gastric bypass recipients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23222033/),h,0.7,98199,DB01124,Tolbutamide
,23222033,tmax,"Compared with controls, the RYGB group had brisk natriuresis, with significantly lower tmax for urine sodium (1.3 ± 0.5 vs 3.1 ± 2.3 hours, P < 0.02) and correspondingly lower tmax for furosemide (1.8 ± 0.3 vs 4.2 ± 1.2 hours, P = 0.006).",Pharmacokinetic and pharmacodynamic alterations in the Roux-en-Y gastric bypass recipients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23222033/),h,1.3,98200,DB01124,Tolbutamide
,23222033,tmax,"Compared with controls, the RYGB group had brisk natriuresis, with significantly lower tmax for urine sodium (1.3 ± 0.5 vs 3.1 ± 2.3 hours, P < 0.02) and correspondingly lower tmax for furosemide (1.8 ± 0.3 vs 4.2 ± 1.2 hours, P = 0.006).",Pharmacokinetic and pharmacodynamic alterations in the Roux-en-Y gastric bypass recipients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23222033/),h,3.1,98201,DB01124,Tolbutamide
,23222033,tmax,"Compared with controls, the RYGB group had brisk natriuresis, with significantly lower tmax for urine sodium (1.3 ± 0.5 vs 3.1 ± 2.3 hours, P < 0.02) and correspondingly lower tmax for furosemide (1.8 ± 0.3 vs 4.2 ± 1.2 hours, P = 0.006).",Pharmacokinetic and pharmacodynamic alterations in the Roux-en-Y gastric bypass recipients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23222033/),h,1.8,98202,DB01124,Tolbutamide
,23222033,tmax,"Compared with controls, the RYGB group had brisk natriuresis, with significantly lower tmax for urine sodium (1.3 ± 0.5 vs 3.1 ± 2.3 hours, P < 0.02) and correspondingly lower tmax for furosemide (1.8 ± 0.3 vs 4.2 ± 1.2 hours, P = 0.006).",Pharmacokinetic and pharmacodynamic alterations in the Roux-en-Y gastric bypass recipients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23222033/),h,4.2,98203,DB01124,Tolbutamide
>,25582505,extraction efficiency,"The extraction efficiency was >90.5%, and the matrix effects ranged from 84.3 to 114.2%.","Simultaneous determination of bupropion, metroprolol, midazolam, phenacetin, omeprazole and tolbutamide in rat plasma by UPLC-MS/MS and its application to cytochrome P450 activity study in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25582505/),%,90.5,101195,DB01124,Tolbutamide
,18793590,apparent oral clearance,"The mean apparent oral clearance (cancer, 19.5 +/- 10.5 vs.",Cytochrome P450 2C9 mediated metabolism in people with and without cancer. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18793590/),,19.5,101244,DB01124,Tolbutamide
,18793590,urinary metabolic ratio,"non-cancer, 15.8 +/- 5.0 ml/min) and the mean urinary metabolic ratio from 0 to 12 h were similar (838 +/- 693 vs. 775 +/- 390).",Cytochrome P450 2C9 mediated metabolism in people with and without cancer. ,Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18793590/),,838,101245,DB01124,Tolbutamide
,18793590,urinary metabolic ratio,"non-cancer, 15.8 +/- 5.0 ml/min) and the mean urinary metabolic ratio from 0 to 12 h were similar (838 +/- 693 vs. 775 +/- 390).",Cytochrome P450 2C9 mediated metabolism in people with and without cancer. ,Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18793590/),,775,101246,DB01124,Tolbutamide
,10915940,maximum of plasma concentration (C(max)),"The pure drug attained a maximum of plasma concentration (C(max)) of 18.58+/-3.27 microg/ml at 8.5 h (T(max)), whereas with inclusion complexes, C(max) increased about two times and appeared at ca. 4 h.",Oral bioavailability and hypoglycaemic activity of tolbutamide/cyclodextrin inclusion complexes. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10915940/),[μg] / [ml],18.58,103431,DB01124,Tolbutamide
,24463402,flow rate,"Analytes were recovered by liquid-liquid extraction and separated on a reverse phase C18 column (150mm×4.6mm i.d., 5μm) using methanol:0.1% formic acid buffer (70:30) as mobile phase at a flow rate of 1mL/min in isocratic mode.","Simultaneous quantification of idelalisib, fludarabine and lenalidomide in rat plasma by using high-performance liquid chromatography coupled with heated electrospray ionization tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24463402/),[ml] / [min],1,103646,DB01124,Tolbutamide
,26354504,K i,CuE (1.25-100 μmol L-1) competitively inhibited tolbutamide 4-hydroxylation (CYP2C11) activity only in concentration-dependent manner with a K i value of 55.5 μmol L-1 in vitro.,In vitro and in vivo evaluation of cucurbitacin E on rat hepatic CYP2C11 expression and activity using LC-MS/MS. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26354504/),[μM] / [l],55.5,104725,DB01124,Tolbutamide
,15258115,intrinsic clearance,"Based on the decrease of the parent compound in the medium, a specific intrinsic clearance value, i.e., clearance per unit of volume of hepatocytes, of 0.085 min(-1) was fitted.",Modeling the in vitro intrinsic clearance of the slowly metabolized compound tolbutamide determined in sandwich-cultured rat hepatocytes. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15258115/),1/[min],0.085,106948,DB01124,Tolbutamide
,15258115,clearance,"Based on the decrease of the parent compound in the medium, a specific intrinsic clearance value, i.e., clearance per unit of volume of hepatocytes, of 0.085 min(-1) was fitted.",Modeling the in vitro intrinsic clearance of the slowly metabolized compound tolbutamide determined in sandwich-cultured rat hepatocytes. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15258115/),1/[min],0.085,106949,DB01124,Tolbutamide
,10976551,formation clearance,The median formation clearance of 3-hydroxyquinidine were 2.40 and 2.33 L/h in the two test periods.,"Quinidine as a probe for CYP3A4 activity: intrasubject variability and lack of correlation with probe-based assays for CYP1A2, CYP2C9, CYP2C19, and CYP2D6. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10976551/),[l] / [h],2.40,109827,DB01124,Tolbutamide
,10976551,formation clearance,The median formation clearance of 3-hydroxyquinidine were 2.40 and 2.33 L/h in the two test periods.,"Quinidine as a probe for CYP3A4 activity: intrasubject variability and lack of correlation with probe-based assays for CYP1A2, CYP2C9, CYP2C19, and CYP2D6. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10976551/),[l] / [h],2.33,109828,DB01124,Tolbutamide
,30981181,flow rate,"Chromatographic separation was performed on a ZORBAX Eclipse Plus C18 Rapid Resolution HD column (2.1 mm × 100 mm, 1.8 μm) with a gradient mobile phase consisting of water containing 2 mM ammonium formate and methanol at a flow rate of 0.2 mL/min over a total run time of 5.0 min.",Development and validation of a sensitive LC-MS/MS method for the determination of 6-hydroxykynurenic acid in rat plasma and its application to pharmacokinetics study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30981181/),[ml] / [min],0.2,117043,DB01124,Tolbutamide
,30981181,total run time,"Chromatographic separation was performed on a ZORBAX Eclipse Plus C18 Rapid Resolution HD column (2.1 mm × 100 mm, 1.8 μm) with a gradient mobile phase consisting of water containing 2 mM ammonium formate and methanol at a flow rate of 0.2 mL/min over a total run time of 5.0 min.",Development and validation of a sensitive LC-MS/MS method for the determination of 6-hydroxykynurenic acid in rat plasma and its application to pharmacokinetics study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30981181/),min,5.0,117044,DB01124,Tolbutamide
,30981181,m/z,The mass spectrometer was operated under multiple reactions monitoring (MRM) mode with the transitions m/z 206.1 → 160.0 for 6-HKA and m/z 269.0 → 170.0 for Tol.,Development and validation of a sensitive LC-MS/MS method for the determination of 6-hydroxykynurenic acid in rat plasma and its application to pharmacokinetics study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30981181/),,206.1,117045,DB01124,Tolbutamide
,30981181,m/z,The mass spectrometer was operated under multiple reactions monitoring (MRM) mode with the transitions m/z 206.1 → 160.0 for 6-HKA and m/z 269.0 → 170.0 for Tol.,Development and validation of a sensitive LC-MS/MS method for the determination of 6-hydroxykynurenic acid in rat plasma and its application to pharmacokinetics study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30981181/),,160.0,117046,DB01124,Tolbutamide
,30981181,m/z,The mass spectrometer was operated under multiple reactions monitoring (MRM) mode with the transitions m/z 206.1 → 160.0 for 6-HKA and m/z 269.0 → 170.0 for Tol.,Development and validation of a sensitive LC-MS/MS method for the determination of 6-hydroxykynurenic acid in rat plasma and its application to pharmacokinetics study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30981181/),,269.0,117047,DB01124,Tolbutamide
,30981181,m/z,The mass spectrometer was operated under multiple reactions monitoring (MRM) mode with the transitions m/z 206.1 → 160.0 for 6-HKA and m/z 269.0 → 170.0 for Tol.,Development and validation of a sensitive LC-MS/MS method for the determination of 6-hydroxykynurenic acid in rat plasma and its application to pharmacokinetics study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30981181/),,170.0,117048,DB01124,Tolbutamide
,30981181,recovery,The mean recovery of 6-HKA in rat plasma was between the range of 99.3-103.4%.,Development and validation of a sensitive LC-MS/MS method for the determination of 6-hydroxykynurenic acid in rat plasma and its application to pharmacokinetics study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30981181/),%,99.3-103.4,117049,DB01124,Tolbutamide
,30981181,bioavailability,"Pharmacokinetic parameters bioavailability, Cmax, oral, Tmax, oral, AUC0-24h, oral, AUC0-∞, oral, AUC0-24h, iv and AUC0-∞, iv were 3.96%, 152.0 ± 85.5 ng/mL, 0.4 ± 0.1 h, 340.0 ± 136.3 ng/mL ∗ h, 369.5 ± 135.0 ng/mL ∗ h, 906.6 ± 324.1 ng/mL*h and 932.9 ± 336.5 ng/mL ∗ h, respectively.",Development and validation of a sensitive LC-MS/MS method for the determination of 6-hydroxykynurenic acid in rat plasma and its application to pharmacokinetics study. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30981181/),%,3.96,117050,DB01124,Tolbutamide
,30981181,AUC0-∞,"Pharmacokinetic parameters bioavailability, Cmax, oral, Tmax, oral, AUC0-24h, oral, AUC0-∞, oral, AUC0-24h, iv and AUC0-∞, iv were 3.96%, 152.0 ± 85.5 ng/mL, 0.4 ± 0.1 h, 340.0 ± 136.3 ng/mL ∗ h, 369.5 ± 135.0 ng/mL ∗ h, 906.6 ± 324.1 ng/mL*h and 932.9 ± 336.5 ng/mL ∗ h, respectively.",Development and validation of a sensitive LC-MS/MS method for the determination of 6-hydroxykynurenic acid in rat plasma and its application to pharmacokinetics study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30981181/),[ng] / [h·ml·∗],932.9,117051,DB01124,Tolbutamide
,2600795,retention times,"The retention times of 3, 2, 1, and the internal standard chlorpropamide were 3.1, 4.1, 14.8, and 10.0 min, respectively.",Simultaneous determinations of tolbutamide and its hydroxy and carboxy metabolites in serum and urine: application to pharmacokinetic studies of tolbutamide in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2600795/),min,3.1,118203,DB01124,Tolbutamide
,2600795,retention times,"The retention times of 3, 2, 1, and the internal standard chlorpropamide were 3.1, 4.1, 14.8, and 10.0 min, respectively.",Simultaneous determinations of tolbutamide and its hydroxy and carboxy metabolites in serum and urine: application to pharmacokinetic studies of tolbutamide in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2600795/),min,4.1,118204,DB01124,Tolbutamide
,2600795,retention times,"The retention times of 3, 2, 1, and the internal standard chlorpropamide were 3.1, 4.1, 14.8, and 10.0 min, respectively.",Simultaneous determinations of tolbutamide and its hydroxy and carboxy metabolites in serum and urine: application to pharmacokinetic studies of tolbutamide in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2600795/),min,14.8,118205,DB01124,Tolbutamide
,2600795,retention times,"The retention times of 3, 2, 1, and the internal standard chlorpropamide were 3.1, 4.1, 14.8, and 10.0 min, respectively.",Simultaneous determinations of tolbutamide and its hydroxy and carboxy metabolites in serum and urine: application to pharmacokinetic studies of tolbutamide in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2600795/),min,10.0,118206,DB01124,Tolbutamide
,2600795,retention times,"Under these conditions, the retention times of the carboxy and hydroxylated metabolites and the internal standard salicylic acid were 4.6, 6.7, and 8.1 min, respectively.",Simultaneous determinations of tolbutamide and its hydroxy and carboxy metabolites in serum and urine: application to pharmacokinetic studies of tolbutamide in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2600795/),min,4.6,118207,DB01124,Tolbutamide
,2600795,retention times,"Under these conditions, the retention times of the carboxy and hydroxylated metabolites and the internal standard salicylic acid were 4.6, 6.7, and 8.1 min, respectively.",Simultaneous determinations of tolbutamide and its hydroxy and carboxy metabolites in serum and urine: application to pharmacokinetic studies of tolbutamide in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2600795/),min,6.7,118208,DB01124,Tolbutamide
,2600795,retention times,"Under these conditions, the retention times of the carboxy and hydroxylated metabolites and the internal standard salicylic acid were 4.6, 6.7, and 8.1 min, respectively.",Simultaneous determinations of tolbutamide and its hydroxy and carboxy metabolites in serum and urine: application to pharmacokinetic studies of tolbutamide in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2600795/),min,8.1,118209,DB01124,Tolbutamide
,23280750,flow rate,"The analytes were extracted by using liquid-liquid extraction and separated on a reverse phase C(18) column (50 mm × 3 mm i.d., 4.6 µ) using methanol: 2 mM ammonium acetate buffer, pH 4.0 as mobile phase at a flow rate 1 mL/min in gradient mode.","Simultaneous quantitation of IC87114, roflumilast and its active metabolite roflumilast N-oxide in plasma by LC-MS/MS: application for a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23280750/),[ml] / [min],1,118624,DB01124,Tolbutamide
,11792681,C(max),"Bergamottin predosing increased the plasma levels of diazepam as observed by C(max) (278.75 ng/ml versus 5.49 ng/ml) and the area under the curve [AUC((0-TLDC))] (247.69 versus 2.79 ng x hr/ml) in bergamottin versus placebo groups, respectively, indicating P450 enzyme inhibition.",The effect of bergamottin on diazepam plasma levels and P450 enzymes in beagle dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11792681/),[ng] / [ml],278.75,118625,DB01124,Tolbutamide
,11792681,C(max),"Bergamottin predosing increased the plasma levels of diazepam as observed by C(max) (278.75 ng/ml versus 5.49 ng/ml) and the area under the curve [AUC((0-TLDC))] (247.69 versus 2.79 ng x hr/ml) in bergamottin versus placebo groups, respectively, indicating P450 enzyme inhibition.",The effect of bergamottin on diazepam plasma levels and P450 enzymes in beagle dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11792681/),[ng] / [ml],5.49,118626,DB01124,Tolbutamide
,11792681,area under the curve [AUC((0-TLDC))],"Bergamottin predosing increased the plasma levels of diazepam as observed by C(max) (278.75 ng/ml versus 5.49 ng/ml) and the area under the curve [AUC((0-TLDC))] (247.69 versus 2.79 ng x hr/ml) in bergamottin versus placebo groups, respectively, indicating P450 enzyme inhibition.",The effect of bergamottin on diazepam plasma levels and P450 enzymes in beagle dogs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11792681/),[h·ng] / [ml],247.69,118627,DB01124,Tolbutamide
,11792681,area under the curve [AUC((0-TLDC))],"Bergamottin predosing increased the plasma levels of diazepam as observed by C(max) (278.75 ng/ml versus 5.49 ng/ml) and the area under the curve [AUC((0-TLDC))] (247.69 versus 2.79 ng x hr/ml) in bergamottin versus placebo groups, respectively, indicating P450 enzyme inhibition.",The effect of bergamottin on diazepam plasma levels and P450 enzymes in beagle dogs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11792681/),[h·ng] / [ml],2.79,118628,DB01124,Tolbutamide
,15333515,systemic clearance,The systemic clearance of propranolol (approximately 1.53 l/h/kg) suggested that the hepatic blood flow in CHPs is comparable to that in humans.,The chimpanzee (Pan troglodytes) as a pharmacokinetic model for selection of drug candidates: model characterization and application. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15333515/),[l] / [h·kg],1.53,119920,DB01124,Tolbutamide
,29403968,flow rate,"The chromatography was performed on a Gl Sciences Inertsil ODS-3 column (100 mm×2.1 mm i.d., 5.0 µm) within 5 min, using methanol with 10 mM ammonium formate (60:40, v/v) as mobile phase at a flow rate of 0.2 mL/min.",Determination of torasemide in human plasma and its bioequivalence study by high-performance liquid chromatography with electrospray ionization tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29403968/),[ml] / [min],0.2,122229,DB01124,Tolbutamide
,29403968,m/z,The targeted compound was detected in negative ionization at m/z 347.00 for torasemide and 269.00 for IS.,Determination of torasemide in human plasma and its bioequivalence study by high-performance liquid chromatography with electrospray ionization tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29403968/),,347.00,122230,DB01124,Tolbutamide
,29403968,m/z,The targeted compound was detected in negative ionization at m/z 347.00 for torasemide and 269.00 for IS.,Determination of torasemide in human plasma and its bioequivalence study by high-performance liquid chromatography with electrospray ionization tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29403968/),,269.00,122231,DB01124,Tolbutamide
,29403968,extracted recovery efficiency,The extracted recovery efficiency was from 84.20% to 86.47% at three concentration levels.,Determination of torasemide in human plasma and its bioequivalence study by high-performance liquid chromatography with electrospray ionization tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29403968/),%,84.20,122232,DB01124,Tolbutamide
,29403968,extracted recovery efficiency,The extracted recovery efficiency was from 84.20% to 86.47% at three concentration levels.,Determination of torasemide in human plasma and its bioequivalence study by high-performance liquid chromatography with electrospray ionization tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29403968/),%,86.47,122233,DB01124,Tolbutamide
,15045499,Plasma clearance,"Plasma clearance and tolbutamide plasma concentrations 24 h after drug intake reflected the genotypes: 0.85 l/h and 1.70 microg/ml (95% confidence interval, CI, 0.80-0.89 l/h and 1.50-1.90 microg/ml) for CYP2C9*1 homozygotes (n=15), 0.77 l/h and 2.14 microg/ml (95%CI, 0.67-0.88 l/h and 1.64-2.63 microg/ml) for *1/*2 genotypes (n=7), 0.60 l/h and 3.13 microg/ml (95%CI, 0.58-0.62 l/h and 2.68-3.58 microg/ml) for *1/*3 genotypes (n=3), and 0.57 l/h and 3.27 microg/ml in the single *2/*2 carrier.",Cytochrome P450 2C9 phenotyping using low-dose tolbutamide. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15045499/),[l] / [h],0.85,123021,DB01124,Tolbutamide
,15045499,Plasma clearance,"Plasma clearance and tolbutamide plasma concentrations 24 h after drug intake reflected the genotypes: 0.85 l/h and 1.70 microg/ml (95% confidence interval, CI, 0.80-0.89 l/h and 1.50-1.90 microg/ml) for CYP2C9*1 homozygotes (n=15), 0.77 l/h and 2.14 microg/ml (95%CI, 0.67-0.88 l/h and 1.64-2.63 microg/ml) for *1/*2 genotypes (n=7), 0.60 l/h and 3.13 microg/ml (95%CI, 0.58-0.62 l/h and 2.68-3.58 microg/ml) for *1/*3 genotypes (n=3), and 0.57 l/h and 3.27 microg/ml in the single *2/*2 carrier.",Cytochrome P450 2C9 phenotyping using low-dose tolbutamide. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15045499/),[μg] / [ml],1.70,123022,DB01124,Tolbutamide
,15045499,Plasma clearance,"Plasma clearance and tolbutamide plasma concentrations 24 h after drug intake reflected the genotypes: 0.85 l/h and 1.70 microg/ml (95% confidence interval, CI, 0.80-0.89 l/h and 1.50-1.90 microg/ml) for CYP2C9*1 homozygotes (n=15), 0.77 l/h and 2.14 microg/ml (95%CI, 0.67-0.88 l/h and 1.64-2.63 microg/ml) for *1/*2 genotypes (n=7), 0.60 l/h and 3.13 microg/ml (95%CI, 0.58-0.62 l/h and 2.68-3.58 microg/ml) for *1/*3 genotypes (n=3), and 0.57 l/h and 3.27 microg/ml in the single *2/*2 carrier.",Cytochrome P450 2C9 phenotyping using low-dose tolbutamide. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15045499/),[l] / [h],0.77,123023,DB01124,Tolbutamide
,15045499,Plasma clearance,"Plasma clearance and tolbutamide plasma concentrations 24 h after drug intake reflected the genotypes: 0.85 l/h and 1.70 microg/ml (95% confidence interval, CI, 0.80-0.89 l/h and 1.50-1.90 microg/ml) for CYP2C9*1 homozygotes (n=15), 0.77 l/h and 2.14 microg/ml (95%CI, 0.67-0.88 l/h and 1.64-2.63 microg/ml) for *1/*2 genotypes (n=7), 0.60 l/h and 3.13 microg/ml (95%CI, 0.58-0.62 l/h and 2.68-3.58 microg/ml) for *1/*3 genotypes (n=3), and 0.57 l/h and 3.27 microg/ml in the single *2/*2 carrier.",Cytochrome P450 2C9 phenotyping using low-dose tolbutamide. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15045499/),[l] / [h],0.60,123024,DB01124,Tolbutamide
,15045499,Plasma clearance,"Plasma clearance and tolbutamide plasma concentrations 24 h after drug intake reflected the genotypes: 0.85 l/h and 1.70 microg/ml (95% confidence interval, CI, 0.80-0.89 l/h and 1.50-1.90 microg/ml) for CYP2C9*1 homozygotes (n=15), 0.77 l/h and 2.14 microg/ml (95%CI, 0.67-0.88 l/h and 1.64-2.63 microg/ml) for *1/*2 genotypes (n=7), 0.60 l/h and 3.13 microg/ml (95%CI, 0.58-0.62 l/h and 2.68-3.58 microg/ml) for *1/*3 genotypes (n=3), and 0.57 l/h and 3.27 microg/ml in the single *2/*2 carrier.",Cytochrome P450 2C9 phenotyping using low-dose tolbutamide. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15045499/),[l] / [h],0.57,123025,DB01124,Tolbutamide
,15045499,tolbutamide,"Plasma clearance and tolbutamide plasma concentrations 24 h after drug intake reflected the genotypes: 0.85 l/h and 1.70 microg/ml (95% confidence interval, CI, 0.80-0.89 l/h and 1.50-1.90 microg/ml) for CYP2C9*1 homozygotes (n=15), 0.77 l/h and 2.14 microg/ml (95%CI, 0.67-0.88 l/h and 1.64-2.63 microg/ml) for *1/*2 genotypes (n=7), 0.60 l/h and 3.13 microg/ml (95%CI, 0.58-0.62 l/h and 2.68-3.58 microg/ml) for *1/*3 genotypes (n=3), and 0.57 l/h and 3.27 microg/ml in the single *2/*2 carrier.",Cytochrome P450 2C9 phenotyping using low-dose tolbutamide. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15045499/),[l] / [h],0.85,123026,DB01124,Tolbutamide
,15045499,tolbutamide,"Plasma clearance and tolbutamide plasma concentrations 24 h after drug intake reflected the genotypes: 0.85 l/h and 1.70 microg/ml (95% confidence interval, CI, 0.80-0.89 l/h and 1.50-1.90 microg/ml) for CYP2C9*1 homozygotes (n=15), 0.77 l/h and 2.14 microg/ml (95%CI, 0.67-0.88 l/h and 1.64-2.63 microg/ml) for *1/*2 genotypes (n=7), 0.60 l/h and 3.13 microg/ml (95%CI, 0.58-0.62 l/h and 2.68-3.58 microg/ml) for *1/*3 genotypes (n=3), and 0.57 l/h and 3.27 microg/ml in the single *2/*2 carrier.",Cytochrome P450 2C9 phenotyping using low-dose tolbutamide. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15045499/),[μg] / [ml],1.70,123027,DB01124,Tolbutamide
,15045499,tolbutamide,"Plasma clearance and tolbutamide plasma concentrations 24 h after drug intake reflected the genotypes: 0.85 l/h and 1.70 microg/ml (95% confidence interval, CI, 0.80-0.89 l/h and 1.50-1.90 microg/ml) for CYP2C9*1 homozygotes (n=15), 0.77 l/h and 2.14 microg/ml (95%CI, 0.67-0.88 l/h and 1.64-2.63 microg/ml) for *1/*2 genotypes (n=7), 0.60 l/h and 3.13 microg/ml (95%CI, 0.58-0.62 l/h and 2.68-3.58 microg/ml) for *1/*3 genotypes (n=3), and 0.57 l/h and 3.27 microg/ml in the single *2/*2 carrier.",Cytochrome P450 2C9 phenotyping using low-dose tolbutamide. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15045499/),[l] / [h],0.77,123028,DB01124,Tolbutamide
,15045499,tolbutamide,"Plasma clearance and tolbutamide plasma concentrations 24 h after drug intake reflected the genotypes: 0.85 l/h and 1.70 microg/ml (95% confidence interval, CI, 0.80-0.89 l/h and 1.50-1.90 microg/ml) for CYP2C9*1 homozygotes (n=15), 0.77 l/h and 2.14 microg/ml (95%CI, 0.67-0.88 l/h and 1.64-2.63 microg/ml) for *1/*2 genotypes (n=7), 0.60 l/h and 3.13 microg/ml (95%CI, 0.58-0.62 l/h and 2.68-3.58 microg/ml) for *1/*3 genotypes (n=3), and 0.57 l/h and 3.27 microg/ml in the single *2/*2 carrier.",Cytochrome P450 2C9 phenotyping using low-dose tolbutamide. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15045499/),[l] / [h],0.60,123029,DB01124,Tolbutamide
,15045499,tolbutamide,"Plasma clearance and tolbutamide plasma concentrations 24 h after drug intake reflected the genotypes: 0.85 l/h and 1.70 microg/ml (95% confidence interval, CI, 0.80-0.89 l/h and 1.50-1.90 microg/ml) for CYP2C9*1 homozygotes (n=15), 0.77 l/h and 2.14 microg/ml (95%CI, 0.67-0.88 l/h and 1.64-2.63 microg/ml) for *1/*2 genotypes (n=7), 0.60 l/h and 3.13 microg/ml (95%CI, 0.58-0.62 l/h and 2.68-3.58 microg/ml) for *1/*3 genotypes (n=3), and 0.57 l/h and 3.27 microg/ml in the single *2/*2 carrier.",Cytochrome P450 2C9 phenotyping using low-dose tolbutamide. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15045499/),[μg] / [ml],3.13,123030,DB01124,Tolbutamide
,15045499,tolbutamide,"Plasma clearance and tolbutamide plasma concentrations 24 h after drug intake reflected the genotypes: 0.85 l/h and 1.70 microg/ml (95% confidence interval, CI, 0.80-0.89 l/h and 1.50-1.90 microg/ml) for CYP2C9*1 homozygotes (n=15), 0.77 l/h and 2.14 microg/ml (95%CI, 0.67-0.88 l/h and 1.64-2.63 microg/ml) for *1/*2 genotypes (n=7), 0.60 l/h and 3.13 microg/ml (95%CI, 0.58-0.62 l/h and 2.68-3.58 microg/ml) for *1/*3 genotypes (n=3), and 0.57 l/h and 3.27 microg/ml in the single *2/*2 carrier.",Cytochrome P450 2C9 phenotyping using low-dose tolbutamide. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15045499/),[l] / [h],0.57,123031,DB01124,Tolbutamide
,15045499,plasma concentrations,"Plasma clearance and tolbutamide plasma concentrations 24 h after drug intake reflected the genotypes: 0.85 l/h and 1.70 microg/ml (95% confidence interval, CI, 0.80-0.89 l/h and 1.50-1.90 microg/ml) for CYP2C9*1 homozygotes (n=15), 0.77 l/h and 2.14 microg/ml (95%CI, 0.67-0.88 l/h and 1.64-2.63 microg/ml) for *1/*2 genotypes (n=7), 0.60 l/h and 3.13 microg/ml (95%CI, 0.58-0.62 l/h and 2.68-3.58 microg/ml) for *1/*3 genotypes (n=3), and 0.57 l/h and 3.27 microg/ml in the single *2/*2 carrier.",Cytochrome P450 2C9 phenotyping using low-dose tolbutamide. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15045499/),[μg] / [ml],1.70,123032,DB01124,Tolbutamide
,15045499,plasma concentrations,"Plasma clearance and tolbutamide plasma concentrations 24 h after drug intake reflected the genotypes: 0.85 l/h and 1.70 microg/ml (95% confidence interval, CI, 0.80-0.89 l/h and 1.50-1.90 microg/ml) for CYP2C9*1 homozygotes (n=15), 0.77 l/h and 2.14 microg/ml (95%CI, 0.67-0.88 l/h and 1.64-2.63 microg/ml) for *1/*2 genotypes (n=7), 0.60 l/h and 3.13 microg/ml (95%CI, 0.58-0.62 l/h and 2.68-3.58 microg/ml) for *1/*3 genotypes (n=3), and 0.57 l/h and 3.27 microg/ml in the single *2/*2 carrier.",Cytochrome P450 2C9 phenotyping using low-dose tolbutamide. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15045499/),[l] / [h],0.60,123033,DB01124,Tolbutamide
,15045499,plasma concentrations,"Plasma clearance and tolbutamide plasma concentrations 24 h after drug intake reflected the genotypes: 0.85 l/h and 1.70 microg/ml (95% confidence interval, CI, 0.80-0.89 l/h and 1.50-1.90 microg/ml) for CYP2C9*1 homozygotes (n=15), 0.77 l/h and 2.14 microg/ml (95%CI, 0.67-0.88 l/h and 1.64-2.63 microg/ml) for *1/*2 genotypes (n=7), 0.60 l/h and 3.13 microg/ml (95%CI, 0.58-0.62 l/h and 2.68-3.58 microg/ml) for *1/*3 genotypes (n=3), and 0.57 l/h and 3.27 microg/ml in the single *2/*2 carrier.",Cytochrome P450 2C9 phenotyping using low-dose tolbutamide. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15045499/),[μg] / [ml],3.13,123034,DB01124,Tolbutamide
,15045499,plasma concentrations,"Plasma clearance and tolbutamide plasma concentrations 24 h after drug intake reflected the genotypes: 0.85 l/h and 1.70 microg/ml (95% confidence interval, CI, 0.80-0.89 l/h and 1.50-1.90 microg/ml) for CYP2C9*1 homozygotes (n=15), 0.77 l/h and 2.14 microg/ml (95%CI, 0.67-0.88 l/h and 1.64-2.63 microg/ml) for *1/*2 genotypes (n=7), 0.60 l/h and 3.13 microg/ml (95%CI, 0.58-0.62 l/h and 2.68-3.58 microg/ml) for *1/*3 genotypes (n=3), and 0.57 l/h and 3.27 microg/ml in the single *2/*2 carrier.",Cytochrome P450 2C9 phenotyping using low-dose tolbutamide. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15045499/),[l] / [h],0.57,123035,DB01124,Tolbutamide
,15045499,plasma concentrations,"Plasma clearance and tolbutamide plasma concentrations 24 h after drug intake reflected the genotypes: 0.85 l/h and 1.70 microg/ml (95% confidence interval, CI, 0.80-0.89 l/h and 1.50-1.90 microg/ml) for CYP2C9*1 homozygotes (n=15), 0.77 l/h and 2.14 microg/ml (95%CI, 0.67-0.88 l/h and 1.64-2.63 microg/ml) for *1/*2 genotypes (n=7), 0.60 l/h and 3.13 microg/ml (95%CI, 0.58-0.62 l/h and 2.68-3.58 microg/ml) for *1/*3 genotypes (n=3), and 0.57 l/h and 3.27 microg/ml in the single *2/*2 carrier.",Cytochrome P450 2C9 phenotyping using low-dose tolbutamide. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15045499/),[μg] / [ml],3.27,123036,DB01124,Tolbutamide
,971708,half life,"The mean DPH half life increased significantly from 11.0 +/- a.2 h to 19.0 +/- 3.3 h, and the mean DPH metabolic clearance rate decreased significantly from 51.2 +/- 17.2 ml/min to 33.9 +/- 12.0 ml/min during medication.",The influence of disulfiram on the half life and metabolic clearance rate of diphenylhydantoin and tolbtamide in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/971708/),h,11.0,125321,DB01124,Tolbutamide
,971708,half life,"The mean DPH half life increased significantly from 11.0 +/- a.2 h to 19.0 +/- 3.3 h, and the mean DPH metabolic clearance rate decreased significantly from 51.2 +/- 17.2 ml/min to 33.9 +/- 12.0 ml/min during medication.",The influence of disulfiram on the half life and metabolic clearance rate of diphenylhydantoin and tolbtamide in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/971708/),h,19.0,125322,DB01124,Tolbutamide
,971708,metabolic clearance rate,"The mean DPH half life increased significantly from 11.0 +/- a.2 h to 19.0 +/- 3.3 h, and the mean DPH metabolic clearance rate decreased significantly from 51.2 +/- 17.2 ml/min to 33.9 +/- 12.0 ml/min during medication.",The influence of disulfiram on the half life and metabolic clearance rate of diphenylhydantoin and tolbtamide in man. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/971708/),[ml] / [min],51.2,125323,DB01124,Tolbutamide
,971708,metabolic clearance rate,"The mean DPH half life increased significantly from 11.0 +/- a.2 h to 19.0 +/- 3.3 h, and the mean DPH metabolic clearance rate decreased significantly from 51.2 +/- 17.2 ml/min to 33.9 +/- 12.0 ml/min during medication.",The influence of disulfiram on the half life and metabolic clearance rate of diphenylhydantoin and tolbtamide in man. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/971708/),[ml] / [min],33.9,125324,DB01124,Tolbutamide
,8801058,Ki,"This approach begins with a determination of an in vitro Ki value (22 microM), which may be used to relate fluconazole plasma concentrations to inhibitory effect on P4502C9 activity and (S)-warfarin half-life.",Warfarin-fluconazole. A rational approach to management of a metabolically based drug interaction. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8801058/),μM,22,128869,DB01124,Tolbutamide
,26922579,flow rate,The flow rate used was 0.7 ml/min on a C18e high performance Chromolith column.,Development and validation of a highly sensitive LC-MS/MS-ESI method for quantification of IIIM-019-A novel nitroimidazole derivative with promising action against Tuberculosis: Application to drug development. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26922579/),[ml] / [min],0.7,134252,DB01124,Tolbutamide
,26922579,oral bioavailability,The oral bioavailability of IIIM-019 was 51.6%.,Development and validation of a highly sensitive LC-MS/MS-ESI method for quantification of IIIM-019-A novel nitroimidazole derivative with promising action against Tuberculosis: Application to drug development. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26922579/),%,51.6,134253,DB01124,Tolbutamide
,31587004,oral bioavailability,"Subsequently, pharmacokinetic study showed that the oral bioavailability of WZ35 is 10.56%.",Cytochrome P450-Mediated Metabolic Characterization of a Mono-Carbonyl Curcumin Analog WZ35. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31587004/),%,10.56,135697,DB01124,Tolbutamide
<,9463023,action period,"The action period for ""short-term"" sulfonamides is < or = 24 h (tolbutamide, glipizide) and can exceed 24 h for ""long-term"" sulfonamides (e.g. glibenclamide).","[Pharmacokinetics of hypoglycemic sulfonamides: Ozidia, a new concept]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9463023/),h,24,140609,DB01124,Tolbutamide
exceed,9463023,action period,"The action period for ""short-term"" sulfonamides is < or = 24 h (tolbutamide, glipizide) and can exceed 24 h for ""long-term"" sulfonamides (e.g. glibenclamide).","[Pharmacokinetics of hypoglycemic sulfonamides: Ozidia, a new concept]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9463023/),h,24,140610,DB01124,Tolbutamide
,15856409,trough concentrations,"On day 11, trough concentrations were 2.0 (range 0.6 - 4.1) microg/L and 1.0 (0.2 - 3.9) microg/L for hypericin and pseudohypericin, respectively, whereas hyperforin concentrations were below the quantification limit (< 1 microg/L).","No relevant interaction with alprazolam, caffeine, tolbutamide, and digoxin by treatment with a low-hyperforin St John's wort extract. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15856409/),[μg] / [l],2.0,142839,DB01124,Tolbutamide
,15856409,trough concentrations,"On day 11, trough concentrations were 2.0 (range 0.6 - 4.1) microg/L and 1.0 (0.2 - 3.9) microg/L for hypericin and pseudohypericin, respectively, whereas hyperforin concentrations were below the quantification limit (< 1 microg/L).","No relevant interaction with alprazolam, caffeine, tolbutamide, and digoxin by treatment with a low-hyperforin St John's wort extract. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15856409/),[μg] / [l],1.0,142840,DB01124,Tolbutamide
,1233266,elimination half-life,The average elimination half-life of hexobarbital had decreased from 325 to 122 min and of tolbutamide from 418 to 183 min following rifampicin treatment.,Induction of drug metabolism in man after rifampicin treatment measured by increased hexobarbital and tolbutamide clearance. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1233266/),min,325 to 122,144728,DB01124,Tolbutamide
,1233266,elimination half-life,The average elimination half-life of hexobarbital had decreased from 325 to 122 min and of tolbutamide from 418 to 183 min following rifampicin treatment.,Induction of drug metabolism in man after rifampicin treatment measured by increased hexobarbital and tolbutamide clearance. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1233266/),min,418 to 183,144729,DB01124,Tolbutamide
,22495777,flow rate,"Chromatographic separation was achieved using an isocratic mobile phase (0.2% formic acid:acetonitrile, 35:65, v/v) at a flow rate of 0.5 mL/min on an Atlantis dC₁₈ column (maintained at 40 ± 1°C) with a total run time of 3.0 min.",Development and validation of a highly sensitive LC-MS/MS-ESI method for the determination of bicalutamide in mouse plasma: application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22495777/),[ml] / [min],0.5,147485,DB01124,Tolbutamide
,22495777,total run time,"Chromatographic separation was achieved using an isocratic mobile phase (0.2% formic acid:acetonitrile, 35:65, v/v) at a flow rate of 0.5 mL/min on an Atlantis dC₁₈ column (maintained at 40 ± 1°C) with a total run time of 3.0 min.",Development and validation of a highly sensitive LC-MS/MS-ESI method for the determination of bicalutamide in mouse plasma: application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22495777/),min,3.0,147486,DB01124,Tolbutamide
,22495777,m/,The MS/MS ion transitions monitored were m/z 428.9 → 254.7 for bicalutamide and m/z 269.0 → 169.6 for IS.,Development and validation of a highly sensitive LC-MS/MS-ESI method for the determination of bicalutamide in mouse plasma: application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22495777/),,428.9,147487,DB01124,Tolbutamide
,22495777,m/,The MS/MS ion transitions monitored were m/z 428.9 → 254.7 for bicalutamide and m/z 269.0 → 169.6 for IS.,Development and validation of a highly sensitive LC-MS/MS-ESI method for the determination of bicalutamide in mouse plasma: application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22495777/),,269.0,147488,DB01124,Tolbutamide
,22495777,m/,The MS/MS ion transitions monitored were m/z 428.9 → 254.7 for bicalutamide and m/z 269.0 → 169.6 for IS.,Development and validation of a highly sensitive LC-MS/MS-ESI method for the determination of bicalutamide in mouse plasma: application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22495777/),,169.6,147489,DB01124,Tolbutamide
,17252192,Vd,"Parametric and nonparametric estimates of Vd for RBC and sucrose were similar and were 0.14+/-0.01, 0.15 0.005 and 0.35+/-0.01 ml/g.",Characterization of the physiological spaces and distribution of tolbutamide in the perfused rat pancreas. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17252192/),[ml] / [g],0.14,147798,DB01124,Tolbutamide
,17252192,Vd,"Parametric and nonparametric estimates of Vd for RBC and sucrose were similar and were 0.14+/-0.01, 0.15 0.005 and 0.35+/-0.01 ml/g.",Characterization of the physiological spaces and distribution of tolbutamide in the perfused rat pancreas. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17252192/),[ml] / [g],0.15,147799,DB01124,Tolbutamide
,17252192,Vd,"Parametric and nonparametric estimates of Vd for RBC and sucrose were similar and were 0.14+/-0.01, 0.15 0.005 and 0.35+/-0.01 ml/g.",Characterization of the physiological spaces and distribution of tolbutamide in the perfused rat pancreas. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17252192/),[ml] / [g],0.005,147800,DB01124,Tolbutamide
,17252192,Vd,"Parametric and nonparametric estimates of Vd for RBC and sucrose were similar and were 0.14+/-0.01, 0.15 0.005 and 0.35+/-0.01 ml/g.",Characterization of the physiological spaces and distribution of tolbutamide in the perfused rat pancreas. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17252192/),[ml] / [g],0.35,147801,DB01124,Tolbutamide
,17252192,water,"The parametric estimate for water, 1.04+/-0.05 ml/g was greater than the nonparametric estimate, 0.89+/-0.02 ml/g.",Characterization of the physiological spaces and distribution of tolbutamide in the perfused rat pancreas. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17252192/),[ml] / [g],1.04,147802,DB01124,Tolbutamide
,17252192,water,"The parametric estimate for water, 1.04+/-0.05 ml/g was greater than the nonparametric estimate, 0.89+/-0.02 ml/g.",Characterization of the physiological spaces and distribution of tolbutamide in the perfused rat pancreas. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17252192/),[ml] / [g],0.89,147803,DB01124,Tolbutamide
,17252192,Vd,The multiple indicator dilution method Vd of tolbutamide of 0.75+0.08 ml/g was similar to the reported value of 0.73+/-0.04 ml/g estimated by tissue partitioning studies.,Characterization of the physiological spaces and distribution of tolbutamide in the perfused rat pancreas. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17252192/),[ml] / [g],0.75,147804,DB01124,Tolbutamide
,17252192,Vd,The multiple indicator dilution method Vd of tolbutamide of 0.75+0.08 ml/g was similar to the reported value of 0.73+/-0.04 ml/g estimated by tissue partitioning studies.,Characterization of the physiological spaces and distribution of tolbutamide in the perfused rat pancreas. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17252192/),[ml] / [g],0.73,147805,DB01124,Tolbutamide
,28403574,flow rate,"An ACQUITY UPLC™ BEH Symmetry Shield RP18 column (1.7 μm, 2.1 mm × 100 mm) was used at a flow rate of 0.3 mL·min-1 .",Determination of artemisitene in rat plasma by ultra-performance liquid chromatography/tandem mass spectrometry and its application in pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28403574/),[ml] / [min],0.3,151942,DB01124,Tolbutamide
,28403574,extraction recoveries,"The extraction recoveries were 61.5-79.4% and 81.7-94.6% for artemisitene and tolbutamide, respectively.",Determination of artemisitene in rat plasma by ultra-performance liquid chromatography/tandem mass spectrometry and its application in pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28403574/),%,61.5-79.4,151943,DB01124,Tolbutamide
,28403574,extraction recoveries,"The extraction recoveries were 61.5-79.4% and 81.7-94.6% for artemisitene and tolbutamide, respectively.",Determination of artemisitene in rat plasma by ultra-performance liquid chromatography/tandem mass spectrometry and its application in pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28403574/),%,81.7-94.6,151944,DB01124,Tolbutamide
,28403574,absolute bioavailability,The absolute bioavailability of artemisitene was 3.7% after intravenous and oral administration in rats.,Determination of artemisitene in rat plasma by ultra-performance liquid chromatography/tandem mass spectrometry and its application in pharmacokinetics. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28403574/),%,3.7,151945,DB01124,Tolbutamide
>,24186263,AUC ratio,The static model predicted in vivo interaction with predicted AUC ratio values of >1.1 for all CYP (except CYP3A4).,"Assessment of interaction potential of AZD2066 using in vitro metabolism tools, physiologically based pharmacokinetic modelling and in vivo cocktail data. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24186263/),,1.1,154701,DB01124,Tolbutamide
,29119333,AUC ratio,"Furthermore, the PBPK simulations in a healthy volunteer population adequately predicted the increase in plasma exposure of tolbutamide in patients with cancer (predicted AUC ratio = 4.7-5.4; measured mean AUC ratio = 5.7).",Physiologically Based Pharmacokinetic Modelling of Cytochrome P450 2C9-Related Tolbutamide Drug Interactions with Sulfaphenazole and Tasisulam. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29119333/),,4.7-5.4,155730,DB01124,Tolbutamide
,29119333,AUC ratio,"Furthermore, the PBPK simulations in a healthy volunteer population adequately predicted the increase in plasma exposure of tolbutamide in patients with cancer (predicted AUC ratio = 4.7-5.4; measured mean AUC ratio = 5.7).",Physiologically Based Pharmacokinetic Modelling of Cytochrome P450 2C9-Related Tolbutamide Drug Interactions with Sulfaphenazole and Tasisulam. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29119333/),,5.7,155731,DB01124,Tolbutamide
,1867959,half-life,3. The mean tolbutamide half-life for 61 of the screened subjects was 7.5 +/- 1.5 h (range 5.2-12.2 h).,A screening test for slow metabolisers of tolbutamide. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1867959/),h,7.5,158605,DB01124,Tolbutamide
,1867959,half-lives,Two subjects had half-lives of 21.6 and 16.1 h.,A screening test for slow metabolisers of tolbutamide. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1867959/),h,21.6,158606,DB01124,Tolbutamide
,1867959,half-lives,Two subjects had half-lives of 21.6 and 16.1 h.,A screening test for slow metabolisers of tolbutamide. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1867959/),h,16.1,158607,DB01124,Tolbutamide
,1867959,half-life,4. The subject with the 21.6 h half-life was restudied with intensive serial sampling for 72 h post-dose.,A screening test for slow metabolisers of tolbutamide. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1867959/),h,21.6,158608,DB01124,Tolbutamide
,1867959,terminal half-life,She was confirmed as a 'slow' metaboliser of tolbutamide since her terminal half-life was 25.9 h but plasma Cmax and tmax were within the range of those in the detailed study.,A screening test for slow metabolisers of tolbutamide. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1867959/),h,25.9,158609,DB01124,Tolbutamide
,16946556,dissociation constants,"The plasma unbound fraction of tolbutamide was higher in ARF rats than in normal rats, and the dissociation constants were 3.5+/-0.7 and 5.5+/-0.2 microg in normal and ARF rats, respectively.",Peritoneal dialysis alters tolbutamide pharmacokinetics in rats with experimental acute renal failure. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16946556/),μg,3.5,158787,DB01124,Tolbutamide
,16946556,dissociation constants,"The plasma unbound fraction of tolbutamide was higher in ARF rats than in normal rats, and the dissociation constants were 3.5+/-0.7 and 5.5+/-0.2 microg in normal and ARF rats, respectively.",Peritoneal dialysis alters tolbutamide pharmacokinetics in rats with experimental acute renal failure. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16946556/),μg,5.5,158788,DB01124,Tolbutamide
,2311340,plasma clearance,"The mean tolbutamide plasma clearance decreased from 0.196 +/- 0.026 ml/min/kg without sulfaphenazole to 0.039 +/- 0.009 ml/min kg with sulfaphenazole, and the mean half-life of tolbutamide increased from 7.28 +/- 0.89 hours to 38.76 +/- 13.30 hours.",Validation of the tolbutamide metabolic ratio for population screening with use of sulfaphenazole to produce model phenotypic poor metabolizers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2311340/),[ml] / [kg·min],0.196,160868,DB01124,Tolbutamide
,2311340,plasma clearance,"The mean tolbutamide plasma clearance decreased from 0.196 +/- 0.026 ml/min/kg without sulfaphenazole to 0.039 +/- 0.009 ml/min kg with sulfaphenazole, and the mean half-life of tolbutamide increased from 7.28 +/- 0.89 hours to 38.76 +/- 13.30 hours.",Validation of the tolbutamide metabolic ratio for population screening with use of sulfaphenazole to produce model phenotypic poor metabolizers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2311340/),[ml] / [kg·min],0.039,160869,DB01124,Tolbutamide
,2311340,half-life,"The mean tolbutamide plasma clearance decreased from 0.196 +/- 0.026 ml/min/kg without sulfaphenazole to 0.039 +/- 0.009 ml/min kg with sulfaphenazole, and the mean half-life of tolbutamide increased from 7.28 +/- 0.89 hours to 38.76 +/- 13.30 hours.",Validation of the tolbutamide metabolic ratio for population screening with use of sulfaphenazole to produce model phenotypic poor metabolizers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2311340/),h,7.28,160870,DB01124,Tolbutamide
,2311340,half-life,"The mean tolbutamide plasma clearance decreased from 0.196 +/- 0.026 ml/min/kg without sulfaphenazole to 0.039 +/- 0.009 ml/min kg with sulfaphenazole, and the mean half-life of tolbutamide increased from 7.28 +/- 0.89 hours to 38.76 +/- 13.30 hours.",Validation of the tolbutamide metabolic ratio for population screening with use of sulfaphenazole to produce model phenotypic poor metabolizers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2311340/),h,38.76,160871,DB01124,Tolbutamide
,2311340,metabolic ratio,"The metabolic ratio determined in the 6 to 12 hour urine collection period decreased from 794.0 +/- 86.6 to 126.0 +/- 79.3, and this collection period also gave the best separation of subjects between phases.",Validation of the tolbutamide metabolic ratio for population screening with use of sulfaphenazole to produce model phenotypic poor metabolizers. ,Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2311340/),,794.0,160872,DB01124,Tolbutamide
,2311340,metabolic ratio,"The metabolic ratio determined in the 6 to 12 hour urine collection period decreased from 794.0 +/- 86.6 to 126.0 +/- 79.3, and this collection period also gave the best separation of subjects between phases.",Validation of the tolbutamide metabolic ratio for population screening with use of sulfaphenazole to produce model phenotypic poor metabolizers. ,Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2311340/),,126.0,160873,DB01124,Tolbutamide
,14749695,systemic clearance,"Echinacea administration significantly increased the systemic clearance of midazolam by 34%, from 32 +/- 7 L/h to 43 +/- 16 L/h (P =.003; 90% confidence interval [CI], 116%-150%), and significantly reduced the midazolam area under the concentration-time curve by 23%, from 127 +/- 36 microg.",The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14749695/),[l] / [h],32,166423,DB01124,Tolbutamide
,14749695,systemic clearance,"Echinacea administration significantly increased the systemic clearance of midazolam by 34%, from 32 +/- 7 L/h to 43 +/- 16 L/h (P =.003; 90% confidence interval [CI], 116%-150%), and significantly reduced the midazolam area under the concentration-time curve by 23%, from 127 +/- 36 microg.",The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14749695/),[l] / [h],43,166424,DB01124,Tolbutamide
,14749695,area under the concentration-time curve,"Echinacea administration significantly increased the systemic clearance of midazolam by 34%, from 32 +/- 7 L/h to 43 +/- 16 L/h (P =.003; 90% confidence interval [CI], 116%-150%), and significantly reduced the midazolam area under the concentration-time curve by 23%, from 127 +/- 36 microg.",The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14749695/),μg,127,166425,DB01124,Tolbutamide
,14749695,oral clearance,"In contrast, the oral clearance of midazolam was not significantly altered (P =.655; 90% CI, 75%-124%), 137 +/- 19 L/h compared with 146 +/- 71 L/h.",The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14749695/),[l] / [h],137,166426,DB01124,Tolbutamide
,14749695,oral clearance,"In contrast, the oral clearance of midazolam was not significantly altered (P =.655; 90% CI, 75%-124%), 137 +/- 19 L/h compared with 146 +/- 71 L/h.",The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14749695/),[l] / [h],146,166427,DB01124,Tolbutamide
,14749695,oral availability,"The oral availability of midazolam after echinacea dosing was significantly increased (P =.028; 90% CI, 108%-153%), from 0.23 +/- 0.06 to 0.33 +/- 0.13.",The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14749695/),%,108,166428,DB01124,Tolbutamide
,14749695,oral availability,"The oral availability of midazolam after echinacea dosing was significantly increased (P =.028; 90% CI, 108%-153%), from 0.23 +/- 0.06 to 0.33 +/- 0.13.",The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14749695/),,0.23,166429,DB01124,Tolbutamide
,14749695,oral availability,"The oral availability of midazolam after echinacea dosing was significantly increased (P =.028; 90% CI, 108%-153%), from 0.23 +/- 0.06 to 0.33 +/- 0.13.",The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14749695/),,0.33,166430,DB01124,Tolbutamide
,14749695,Hepatic availability,"Hepatic availability (0.72 +/- 0.08 versus 0.61 +/- 0.16; P =.006; 90% CI, 73%-90%) and intestinal availability (0.33 +/- 0.11 versus 0.61 +/- 0.38; P =.015; 90% CI, 125%-203%) were significantly altered in opposite directions.",The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo. ,FH-Q42,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14749695/),,0.72,166431,DB01124,Tolbutamide
,14749695,Hepatic availability,"Hepatic availability (0.72 +/- 0.08 versus 0.61 +/- 0.16; P =.006; 90% CI, 73%-90%) and intestinal availability (0.33 +/- 0.11 versus 0.61 +/- 0.38; P =.015; 90% CI, 125%-203%) were significantly altered in opposite directions.",The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo. ,FH-Q42,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14749695/),,0.61,166432,DB01124,Tolbutamide
,14749695,intestinal availability,"Hepatic availability (0.72 +/- 0.08 versus 0.61 +/- 0.16; P =.006; 90% CI, 73%-90%) and intestinal availability (0.33 +/- 0.11 versus 0.61 +/- 0.38; P =.015; 90% CI, 125%-203%) were significantly altered in opposite directions.",The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14749695/),,0.33,166433,DB01124,Tolbutamide
,14749695,intestinal availability,"Hepatic availability (0.72 +/- 0.08 versus 0.61 +/- 0.16; P =.006; 90% CI, 73%-90%) and intestinal availability (0.33 +/- 0.11 versus 0.61 +/- 0.38; P =.015; 90% CI, 125%-203%) were significantly altered in opposite directions.",The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14749695/),,0.61,166434,DB01124,Tolbutamide
,14749695,oral clearance,"Echinacea dosing significantly reduced the oral clearance of caffeine, from 6.6 +/- 3.8 L/h to 4.9 +/- 2.3 L/h (P =.049; 90% CI, 58%-96%).",The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14749695/),[l] / [h],6.6,166435,DB01124,Tolbutamide
,14749695,oral clearance,"Echinacea dosing significantly reduced the oral clearance of caffeine, from 6.6 +/- 3.8 L/h to 4.9 +/- 2.3 L/h (P =.049; 90% CI, 58%-96%).",The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14749695/),[l] / [h],4.9,166436,DB01124,Tolbutamide
,14749695,oral clearance,"The oral clearance of tolbutamide was reduced by 11%, from 0.81 +/- 0.18 L/h to 0.72 +/- 0.19 L/h, but this change was not considered to be clinically relevant because the 90% CIs were within the 80% to 125% range.",The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14749695/),[l] / [h],0.81,166437,DB01124,Tolbutamide
,14749695,oral clearance,"The oral clearance of tolbutamide was reduced by 11%, from 0.81 +/- 0.18 L/h to 0.72 +/- 0.19 L/h, but this change was not considered to be clinically relevant because the 90% CIs were within the 80% to 125% range.",The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14749695/),[l] / [h],0.72,166438,DB01124,Tolbutamide
,14749695,oral clearance,"The oral clearance of dextromethorphan in 11 CYP2D6 extensive metabolizers was not affected by echinacea dosing (1289 +/- 414 L/h compared with 1281 +/- 483 L/h; P =.732; 90% CI, 89%-108%).",The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14749695/),[l] / [h],1289,166439,DB01124,Tolbutamide
,14749695,oral clearance,"The oral clearance of dextromethorphan in 11 CYP2D6 extensive metabolizers was not affected by echinacea dosing (1289 +/- 414 L/h compared with 1281 +/- 483 L/h; P =.732; 90% CI, 89%-108%).",The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14749695/),[l] / [h],1281,166440,DB01124,Tolbutamide
,24899600,AUC(0-t),"The pharmacokinetics parameter of tolbutamide in ADR-group and Control-group were AUC(0-t) 15.371 ± 4.107, 6.901 ± 5.738 (mg/L*h), MRT(0-t) 8.751 ± 0.754, 6.032 ± 0.63 (h), t1/2 3.88 ± 0.423, 3.602 ± 0.693 (h), Tmax 6.2 ± 3.768, 1.95 ± 0.798 (h), CL/F 0.038 ± 0.005, 0.107 ± 0.037 (L/h/kg), V/F 0.212 ± 0.043, 0.567 ± 0.258 (L/kg), Cmax 1.853 ± 0.384, 1.422 ± 1.312 (mg/L).",Pharmacokinetic of four probe drugs in adriamycin-induced nephropathy rat. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24899600/),[mg] / [h·l],15.371,167278,DB01124,Tolbutamide
,24899600,AUC(0-t),"The pharmacokinetics parameter of tolbutamide in ADR-group and Control-group were AUC(0-t) 15.371 ± 4.107, 6.901 ± 5.738 (mg/L*h), MRT(0-t) 8.751 ± 0.754, 6.032 ± 0.63 (h), t1/2 3.88 ± 0.423, 3.602 ± 0.693 (h), Tmax 6.2 ± 3.768, 1.95 ± 0.798 (h), CL/F 0.038 ± 0.005, 0.107 ± 0.037 (L/h/kg), V/F 0.212 ± 0.043, 0.567 ± 0.258 (L/kg), Cmax 1.853 ± 0.384, 1.422 ± 1.312 (mg/L).",Pharmacokinetic of four probe drugs in adriamycin-induced nephropathy rat. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24899600/),[mg] / [h·l],6.901,167279,DB01124,Tolbutamide
,24899600,MRT(0-t),"The pharmacokinetics parameter of tolbutamide in ADR-group and Control-group were AUC(0-t) 15.371 ± 4.107, 6.901 ± 5.738 (mg/L*h), MRT(0-t) 8.751 ± 0.754, 6.032 ± 0.63 (h), t1/2 3.88 ± 0.423, 3.602 ± 0.693 (h), Tmax 6.2 ± 3.768, 1.95 ± 0.798 (h), CL/F 0.038 ± 0.005, 0.107 ± 0.037 (L/h/kg), V/F 0.212 ± 0.043, 0.567 ± 0.258 (L/kg), Cmax 1.853 ± 0.384, 1.422 ± 1.312 (mg/L).",Pharmacokinetic of four probe drugs in adriamycin-induced nephropathy rat. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24899600/),h,8.751,167280,DB01124,Tolbutamide
,24899600,MRT(0-t),"The pharmacokinetics parameter of tolbutamide in ADR-group and Control-group were AUC(0-t) 15.371 ± 4.107, 6.901 ± 5.738 (mg/L*h), MRT(0-t) 8.751 ± 0.754, 6.032 ± 0.63 (h), t1/2 3.88 ± 0.423, 3.602 ± 0.693 (h), Tmax 6.2 ± 3.768, 1.95 ± 0.798 (h), CL/F 0.038 ± 0.005, 0.107 ± 0.037 (L/h/kg), V/F 0.212 ± 0.043, 0.567 ± 0.258 (L/kg), Cmax 1.853 ± 0.384, 1.422 ± 1.312 (mg/L).",Pharmacokinetic of four probe drugs in adriamycin-induced nephropathy rat. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24899600/),h,6.032,167281,DB01124,Tolbutamide
,24899600,t1/2,"The pharmacokinetics parameter of tolbutamide in ADR-group and Control-group were AUC(0-t) 15.371 ± 4.107, 6.901 ± 5.738 (mg/L*h), MRT(0-t) 8.751 ± 0.754, 6.032 ± 0.63 (h), t1/2 3.88 ± 0.423, 3.602 ± 0.693 (h), Tmax 6.2 ± 3.768, 1.95 ± 0.798 (h), CL/F 0.038 ± 0.005, 0.107 ± 0.037 (L/h/kg), V/F 0.212 ± 0.043, 0.567 ± 0.258 (L/kg), Cmax 1.853 ± 0.384, 1.422 ± 1.312 (mg/L).",Pharmacokinetic of four probe drugs in adriamycin-induced nephropathy rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24899600/),h,3.88,167282,DB01124,Tolbutamide
,24899600,t1/2,"The pharmacokinetics parameter of tolbutamide in ADR-group and Control-group were AUC(0-t) 15.371 ± 4.107, 6.901 ± 5.738 (mg/L*h), MRT(0-t) 8.751 ± 0.754, 6.032 ± 0.63 (h), t1/2 3.88 ± 0.423, 3.602 ± 0.693 (h), Tmax 6.2 ± 3.768, 1.95 ± 0.798 (h), CL/F 0.038 ± 0.005, 0.107 ± 0.037 (L/h/kg), V/F 0.212 ± 0.043, 0.567 ± 0.258 (L/kg), Cmax 1.853 ± 0.384, 1.422 ± 1.312 (mg/L).",Pharmacokinetic of four probe drugs in adriamycin-induced nephropathy rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24899600/),h,3.602,167283,DB01124,Tolbutamide
,24899600,Tmax,"The pharmacokinetics parameter of tolbutamide in ADR-group and Control-group were AUC(0-t) 15.371 ± 4.107, 6.901 ± 5.738 (mg/L*h), MRT(0-t) 8.751 ± 0.754, 6.032 ± 0.63 (h), t1/2 3.88 ± 0.423, 3.602 ± 0.693 (h), Tmax 6.2 ± 3.768, 1.95 ± 0.798 (h), CL/F 0.038 ± 0.005, 0.107 ± 0.037 (L/h/kg), V/F 0.212 ± 0.043, 0.567 ± 0.258 (L/kg), Cmax 1.853 ± 0.384, 1.422 ± 1.312 (mg/L).",Pharmacokinetic of four probe drugs in adriamycin-induced nephropathy rat. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24899600/),h,6.2,167284,DB01124,Tolbutamide
,24899600,Tmax,"The pharmacokinetics parameter of tolbutamide in ADR-group and Control-group were AUC(0-t) 15.371 ± 4.107, 6.901 ± 5.738 (mg/L*h), MRT(0-t) 8.751 ± 0.754, 6.032 ± 0.63 (h), t1/2 3.88 ± 0.423, 3.602 ± 0.693 (h), Tmax 6.2 ± 3.768, 1.95 ± 0.798 (h), CL/F 0.038 ± 0.005, 0.107 ± 0.037 (L/h/kg), V/F 0.212 ± 0.043, 0.567 ± 0.258 (L/kg), Cmax 1.853 ± 0.384, 1.422 ± 1.312 (mg/L).",Pharmacokinetic of four probe drugs in adriamycin-induced nephropathy rat. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24899600/),h,1.95,167285,DB01124,Tolbutamide
,24899600,CL/F,"The pharmacokinetics parameter of tolbutamide in ADR-group and Control-group were AUC(0-t) 15.371 ± 4.107, 6.901 ± 5.738 (mg/L*h), MRT(0-t) 8.751 ± 0.754, 6.032 ± 0.63 (h), t1/2 3.88 ± 0.423, 3.602 ± 0.693 (h), Tmax 6.2 ± 3.768, 1.95 ± 0.798 (h), CL/F 0.038 ± 0.005, 0.107 ± 0.037 (L/h/kg), V/F 0.212 ± 0.043, 0.567 ± 0.258 (L/kg), Cmax 1.853 ± 0.384, 1.422 ± 1.312 (mg/L).",Pharmacokinetic of four probe drugs in adriamycin-induced nephropathy rat. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24899600/),[l] / [h·kg],0.038,167286,DB01124,Tolbutamide
,24899600,CL/F,"The pharmacokinetics parameter of tolbutamide in ADR-group and Control-group were AUC(0-t) 15.371 ± 4.107, 6.901 ± 5.738 (mg/L*h), MRT(0-t) 8.751 ± 0.754, 6.032 ± 0.63 (h), t1/2 3.88 ± 0.423, 3.602 ± 0.693 (h), Tmax 6.2 ± 3.768, 1.95 ± 0.798 (h), CL/F 0.038 ± 0.005, 0.107 ± 0.037 (L/h/kg), V/F 0.212 ± 0.043, 0.567 ± 0.258 (L/kg), Cmax 1.853 ± 0.384, 1.422 ± 1.312 (mg/L).",Pharmacokinetic of four probe drugs in adriamycin-induced nephropathy rat. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24899600/),[l] / [h·kg],0.107,167287,DB01124,Tolbutamide
,24899600,V/F,"The pharmacokinetics parameter of tolbutamide in ADR-group and Control-group were AUC(0-t) 15.371 ± 4.107, 6.901 ± 5.738 (mg/L*h), MRT(0-t) 8.751 ± 0.754, 6.032 ± 0.63 (h), t1/2 3.88 ± 0.423, 3.602 ± 0.693 (h), Tmax 6.2 ± 3.768, 1.95 ± 0.798 (h), CL/F 0.038 ± 0.005, 0.107 ± 0.037 (L/h/kg), V/F 0.212 ± 0.043, 0.567 ± 0.258 (L/kg), Cmax 1.853 ± 0.384, 1.422 ± 1.312 (mg/L).",Pharmacokinetic of four probe drugs in adriamycin-induced nephropathy rat. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24899600/),[l] / [kg],0.212,167288,DB01124,Tolbutamide
,24899600,V/F,"The pharmacokinetics parameter of tolbutamide in ADR-group and Control-group were AUC(0-t) 15.371 ± 4.107, 6.901 ± 5.738 (mg/L*h), MRT(0-t) 8.751 ± 0.754, 6.032 ± 0.63 (h), t1/2 3.88 ± 0.423, 3.602 ± 0.693 (h), Tmax 6.2 ± 3.768, 1.95 ± 0.798 (h), CL/F 0.038 ± 0.005, 0.107 ± 0.037 (L/h/kg), V/F 0.212 ± 0.043, 0.567 ± 0.258 (L/kg), Cmax 1.853 ± 0.384, 1.422 ± 1.312 (mg/L).",Pharmacokinetic of four probe drugs in adriamycin-induced nephropathy rat. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24899600/),[l] / [kg],0.567,167289,DB01124,Tolbutamide
,24899600,Cmax,"The pharmacokinetics parameter of tolbutamide in ADR-group and Control-group were AUC(0-t) 15.371 ± 4.107, 6.901 ± 5.738 (mg/L*h), MRT(0-t) 8.751 ± 0.754, 6.032 ± 0.63 (h), t1/2 3.88 ± 0.423, 3.602 ± 0.693 (h), Tmax 6.2 ± 3.768, 1.95 ± 0.798 (h), CL/F 0.038 ± 0.005, 0.107 ± 0.037 (L/h/kg), V/F 0.212 ± 0.043, 0.567 ± 0.258 (L/kg), Cmax 1.853 ± 0.384, 1.422 ± 1.312 (mg/L).",Pharmacokinetic of four probe drugs in adriamycin-induced nephropathy rat. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24899600/),[mg] / [l],1.853,167290,DB01124,Tolbutamide
,24899600,Cmax,"The pharmacokinetics parameter of tolbutamide in ADR-group and Control-group were AUC(0-t) 15.371 ± 4.107, 6.901 ± 5.738 (mg/L*h), MRT(0-t) 8.751 ± 0.754, 6.032 ± 0.63 (h), t1/2 3.88 ± 0.423, 3.602 ± 0.693 (h), Tmax 6.2 ± 3.768, 1.95 ± 0.798 (h), CL/F 0.038 ± 0.005, 0.107 ± 0.037 (L/h/kg), V/F 0.212 ± 0.043, 0.567 ± 0.258 (L/kg), Cmax 1.853 ± 0.384, 1.422 ± 1.312 (mg/L).",Pharmacokinetic of four probe drugs in adriamycin-induced nephropathy rat. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24899600/),[mg] / [l],1.422,167291,DB01124,Tolbutamide
,2556239,plasma half-life,It has a plasma half-life of approximately 25-30 hr and approximately 70% of dose is excreted in the urine unchanged.,Review of fluconazole: a new triazole antifungal agent. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2556239/),h,25-30,169591,DB01124,Tolbutamide
,2515863,terminal phase half-life,"The terminal phase half-life of glibenclamide was 2.46 +/- 0.67 h (mean +/- SD), total drug clearance was 48.7 +/- 11.0 ml.min-1 and the slow disposition phase rate constant was 0.30 +/- 0.08 h-1.",Uniform elimination pattern for glibenclamide in healthy Caucasian males. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2515863/),h,2.46,177791,DB01124,Tolbutamide
,2515863,total drug clearance,"The terminal phase half-life of glibenclamide was 2.46 +/- 0.67 h (mean +/- SD), total drug clearance was 48.7 +/- 11.0 ml.min-1 and the slow disposition phase rate constant was 0.30 +/- 0.08 h-1.",Uniform elimination pattern for glibenclamide in healthy Caucasian males. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2515863/),[ml] / [min],48.7,177792,DB01124,Tolbutamide
,2515863,slow disposition phase rate constant,"The terminal phase half-life of glibenclamide was 2.46 +/- 0.67 h (mean +/- SD), total drug clearance was 48.7 +/- 11.0 ml.min-1 and the slow disposition phase rate constant was 0.30 +/- 0.08 h-1.",Uniform elimination pattern for glibenclamide in healthy Caucasian males. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2515863/),1/[h],0.30,177793,DB01124,Tolbutamide
,32725383,Vss ratio,"Changes in exposure (area under the curve) up to 5.1-fold were observed; however, ratios of Vss changes have a range of 0.70-1.26, with one outlier displaying a Vss ratio of 0.57.",Volume of Distribution is Unaffected by Metabolic Drug-Drug Interactions. ,Css ratio-Q35,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32725383/),,0.57,192758,DB01124,Tolbutamide
,19679455,K(i),"The K(i) values of the tanshinones were: dihydrotanshinone (8.92microM), cryptotanshinone (24.5microM), tanshinone I (80.3microM) and tanshinone IIA (242.9microM).","Pharmacokinetic interaction studies of tanshinones with tolbutamide, a model CYP2C11 probe substrate, using liver microsomes, primary hepatocytes and in vivo in the rat. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19679455/),μM,8.92,194747,DB01124,Tolbutamide
,19679455,K(i),"The K(i) values of the tanshinones were: dihydrotanshinone (8.92microM), cryptotanshinone (24.5microM), tanshinone I (80.3microM) and tanshinone IIA (242.9microM).","Pharmacokinetic interaction studies of tanshinones with tolbutamide, a model CYP2C11 probe substrate, using liver microsomes, primary hepatocytes and in vivo in the rat. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19679455/),μM,24.5,194748,DB01124,Tolbutamide
,19679455,K(i),"The K(i) values of the tanshinones were: dihydrotanshinone (8.92microM), cryptotanshinone (24.5microM), tanshinone I (80.3microM) and tanshinone IIA (242.9microM).","Pharmacokinetic interaction studies of tanshinones with tolbutamide, a model CYP2C11 probe substrate, using liver microsomes, primary hepatocytes and in vivo in the rat. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19679455/),μM,80.3,194749,DB01124,Tolbutamide
,19679455,K(i),"The K(i) values of the tanshinones were: dihydrotanshinone (8.92microM), cryptotanshinone (24.5microM), tanshinone I (80.3microM) and tanshinone IIA (242.9microM).","Pharmacokinetic interaction studies of tanshinones with tolbutamide, a model CYP2C11 probe substrate, using liver microsomes, primary hepatocytes and in vivo in the rat. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19679455/),μM,242.9,194750,DB01124,Tolbutamide
,19679455,EC(40),"In freshly prepared primary rat hepatocytes, tanshinones inhibited tolbutamide 4-hydroxylation in a concentration-dependent manner, with EC(40) values in the order: cryptotanshinone (15.8microM), tanshinone IIA (16.2microM), dihydrotanshinone (20.1microM) and tanshinone I (48.2microM).","Pharmacokinetic interaction studies of tanshinones with tolbutamide, a model CYP2C11 probe substrate, using liver microsomes, primary hepatocytes and in vivo in the rat. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19679455/),μM,15.8,194751,DB01124,Tolbutamide
,19679455,EC(40),"In freshly prepared primary rat hepatocytes, tanshinones inhibited tolbutamide 4-hydroxylation in a concentration-dependent manner, with EC(40) values in the order: cryptotanshinone (15.8microM), tanshinone IIA (16.2microM), dihydrotanshinone (20.1microM) and tanshinone I (48.2microM).","Pharmacokinetic interaction studies of tanshinones with tolbutamide, a model CYP2C11 probe substrate, using liver microsomes, primary hepatocytes and in vivo in the rat. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19679455/),μM,16.2,194752,DB01124,Tolbutamide
,19679455,EC(40),"In freshly prepared primary rat hepatocytes, tanshinones inhibited tolbutamide 4-hydroxylation in a concentration-dependent manner, with EC(40) values in the order: cryptotanshinone (15.8microM), tanshinone IIA (16.2microM), dihydrotanshinone (20.1microM) and tanshinone I (48.2microM).","Pharmacokinetic interaction studies of tanshinones with tolbutamide, a model CYP2C11 probe substrate, using liver microsomes, primary hepatocytes and in vivo in the rat. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19679455/),μM,20.1,194753,DB01124,Tolbutamide
,19679455,EC(40),"In freshly prepared primary rat hepatocytes, tanshinones inhibited tolbutamide 4-hydroxylation in a concentration-dependent manner, with EC(40) values in the order: cryptotanshinone (15.8microM), tanshinone IIA (16.2microM), dihydrotanshinone (20.1microM) and tanshinone I (48.2microM).","Pharmacokinetic interaction studies of tanshinones with tolbutamide, a model CYP2C11 probe substrate, using liver microsomes, primary hepatocytes and in vivo in the rat. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19679455/),μM,48.2,194754,DB01124,Tolbutamide
,24431079,IC50,The most potent CYP2C inhibitor identified in vitro was tamarixetin (IC50 = 1.4 μM).,Dietary flavonoids modulate CYP2C to improve drug oral bioavailability and their qualitative/quantitative structure-activity relationship. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24431079/),μM,1.4,197658,DB01124,Tolbutamide
,10190649,Cmax,"Pharmacokinetic parameters in Chinese (mean+/-s.d.) including Cmax (63+/-11 microg ml(-1)), tmax (median 3.3 h; range 1.6-6.0 h), V/F (9.1+/-1.7 l) and t1/2, (9.1 h; harmonic mean) were similar to the values in Caucasians.",Pharmacokinetics of tolbutamide in ethnic Chinese. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10190649/),[μg] / [ml],63,201259,DB01124,Tolbutamide
,10190649,tmax,"Pharmacokinetic parameters in Chinese (mean+/-s.d.) including Cmax (63+/-11 microg ml(-1)), tmax (median 3.3 h; range 1.6-6.0 h), V/F (9.1+/-1.7 l) and t1/2, (9.1 h; harmonic mean) were similar to the values in Caucasians.",Pharmacokinetics of tolbutamide in ethnic Chinese. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10190649/),h,3.3,201260,DB01124,Tolbutamide
,10190649,V/F,"Pharmacokinetic parameters in Chinese (mean+/-s.d.) including Cmax (63+/-11 microg ml(-1)), tmax (median 3.3 h; range 1.6-6.0 h), V/F (9.1+/-1.7 l) and t1/2, (9.1 h; harmonic mean) were similar to the values in Caucasians.",Pharmacokinetics of tolbutamide in ethnic Chinese. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10190649/),l,9.1,201261,DB01124,Tolbutamide
,10190649,t1/2,"Pharmacokinetic parameters in Chinese (mean+/-s.d.) including Cmax (63+/-11 microg ml(-1)), tmax (median 3.3 h; range 1.6-6.0 h), V/F (9.1+/-1.7 l) and t1/2, (9.1 h; harmonic mean) were similar to the values in Caucasians.",Pharmacokinetics of tolbutamide in ethnic Chinese. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10190649/),h,9.1,201262,DB01124,Tolbutamide
,10190649,CL/F,CL/F (637+/-88 ml h(-1)) was higher in Chinese than Caucasians.,Pharmacokinetics of tolbutamide in ethnic Chinese. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10190649/),[ml] / [h],637,201263,DB01124,Tolbutamide
,10190649,urinary recoveries,The urinary recoveries of hydroxytolbutamide (13+/-1% of dose) and carboxytolbutamide (68+/-5% of dose) and the partial apparent metabolic clearance (0.15+/-0.02 ml min(-1) kg(-1)) in Chinese were comparable with Caucasians.,Pharmacokinetics of tolbutamide in ethnic Chinese. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10190649/),%,13,201264,DB01124,Tolbutamide
,10190649,urinary recoveries,The urinary recoveries of hydroxytolbutamide (13+/-1% of dose) and carboxytolbutamide (68+/-5% of dose) and the partial apparent metabolic clearance (0.15+/-0.02 ml min(-1) kg(-1)) in Chinese were comparable with Caucasians.,Pharmacokinetics of tolbutamide in ethnic Chinese. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10190649/),%,68,201265,DB01124,Tolbutamide
,10190649,partial apparent metabolic clearance,The urinary recoveries of hydroxytolbutamide (13+/-1% of dose) and carboxytolbutamide (68+/-5% of dose) and the partial apparent metabolic clearance (0.15+/-0.02 ml min(-1) kg(-1)) in Chinese were comparable with Caucasians.,Pharmacokinetics of tolbutamide in ethnic Chinese. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10190649/),[ml] / [kg·min],0.15,201266,DB01124,Tolbutamide
,9021442,AUC0-48,"The mean AUC0-48 values are nearly identical (998.42 vs. 997.73 micrograms x h x ml-1), while the Cmax values (51.1 vs. 58.8 micrograms/ml) and the tmax values (4.55 vs. 3.82 h) show slight differences.",Bioequivalence of tolbutamide-containing tablet preparations. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9021442/),[h·μg] / [ml],998.42,201363,DB01124,Tolbutamide
,9021442,AUC0-48,"The mean AUC0-48 values are nearly identical (998.42 vs. 997.73 micrograms x h x ml-1), while the Cmax values (51.1 vs. 58.8 micrograms/ml) and the tmax values (4.55 vs. 3.82 h) show slight differences.",Bioequivalence of tolbutamide-containing tablet preparations. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9021442/),[h·μg] / [ml],997.73,201364,DB01124,Tolbutamide
,9021442,Cmax,"The mean AUC0-48 values are nearly identical (998.42 vs. 997.73 micrograms x h x ml-1), while the Cmax values (51.1 vs. 58.8 micrograms/ml) and the tmax values (4.55 vs. 3.82 h) show slight differences.",Bioequivalence of tolbutamide-containing tablet preparations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9021442/),[μg] / [ml],51.1,201365,DB01124,Tolbutamide
,9021442,Cmax,"The mean AUC0-48 values are nearly identical (998.42 vs. 997.73 micrograms x h x ml-1), while the Cmax values (51.1 vs. 58.8 micrograms/ml) and the tmax values (4.55 vs. 3.82 h) show slight differences.",Bioequivalence of tolbutamide-containing tablet preparations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9021442/),[μg] / [ml],58.8,201366,DB01124,Tolbutamide
,9021442,tmax,"The mean AUC0-48 values are nearly identical (998.42 vs. 997.73 micrograms x h x ml-1), while the Cmax values (51.1 vs. 58.8 micrograms/ml) and the tmax values (4.55 vs. 3.82 h) show slight differences.",Bioequivalence of tolbutamide-containing tablet preparations. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9021442/),h,4.55,201367,DB01124,Tolbutamide
,9021442,tmax,"The mean AUC0-48 values are nearly identical (998.42 vs. 997.73 micrograms x h x ml-1), while the Cmax values (51.1 vs. 58.8 micrograms/ml) and the tmax values (4.55 vs. 3.82 h) show slight differences.",Bioequivalence of tolbutamide-containing tablet preparations. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9021442/),h,3.82,201368,DB01124,Tolbutamide
,32055590,m,"Mass spectrometric detection and quantitation were conducted by selected reaction-monitoring on a negative electrospray ionization mode with the following transitions: m/z 521.11 → 361.10, 477.03 → 361.10, and 269.00 → 169.60 for ticagrelor, AR-C124910XX, and tolbutamide, respectively.","Simultaneous quantification of ticagrelor and its active metabolite, AR-C124910XX, in human plasma by liquid chromatography-tandem mass spectrometry: Applications in steady-state pharmacokinetics in patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32055590/),,521.11,203077,DB01124,Tolbutamide
,32055590,m,"Mass spectrometric detection and quantitation were conducted by selected reaction-monitoring on a negative electrospray ionization mode with the following transitions: m/z 521.11 → 361.10, 477.03 → 361.10, and 269.00 → 169.60 for ticagrelor, AR-C124910XX, and tolbutamide, respectively.","Simultaneous quantification of ticagrelor and its active metabolite, AR-C124910XX, in human plasma by liquid chromatography-tandem mass spectrometry: Applications in steady-state pharmacokinetics in patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32055590/),,477.03,203078,DB01124,Tolbutamide
,32055590,m,"Mass spectrometric detection and quantitation were conducted by selected reaction-monitoring on a negative electrospray ionization mode with the following transitions: m/z 521.11 → 361.10, 477.03 → 361.10, and 269.00 → 169.60 for ticagrelor, AR-C124910XX, and tolbutamide, respectively.","Simultaneous quantification of ticagrelor and its active metabolite, AR-C124910XX, in human plasma by liquid chromatography-tandem mass spectrometry: Applications in steady-state pharmacokinetics in patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32055590/),,269.00,203079,DB01124,Tolbutamide
,862650,elimination half-life,The average elimination half-life of hexobarbital had decreased from 624 to 262 min and that of tolbutamide from 292 to 160 min following rifampicin treatment.,Stimulation of drug metabolism by rifampicin in patients with cirrhosis or cholestasis measured by increased hexobarbital and tolbutamide clearance. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/862650/),min,624 to 262,205510,DB01124,Tolbutamide
,862650,elimination half-life,The average elimination half-life of hexobarbital had decreased from 624 to 262 min and that of tolbutamide from 292 to 160 min following rifampicin treatment.,Stimulation of drug metabolism by rifampicin in patients with cirrhosis or cholestasis measured by increased hexobarbital and tolbutamide clearance. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/862650/),min,292 to 160,205511,DB01124,Tolbutamide
,22305081,Precision,"Precision of the three analytes in the same order ranged from 0.8 to 2.8%, 2.4 to 5.7%, and 2.4 to 2.8%.","Quantification of irinotecan, SN38, and SN38G in human and porcine plasma by ultra high-performance liquid chromatography-tandem mass spectrometry and its application to hepatic chemoembolization. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22305081/),%,0.8 to 2.8,207749,DB01124,Tolbutamide
,22305081,Precision,"Precision of the three analytes in the same order ranged from 0.8 to 2.8%, 2.4 to 5.7%, and 2.4 to 2.8%.","Quantification of irinotecan, SN38, and SN38G in human and porcine plasma by ultra high-performance liquid chromatography-tandem mass spectrometry and its application to hepatic chemoembolization. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22305081/),%,2.4 to 5.7,207750,DB01124,Tolbutamide
,22305081,Precision,"Precision of the three analytes in the same order ranged from 0.8 to 2.8%, 2.4 to 5.7%, and 2.4 to 2.8%.","Quantification of irinotecan, SN38, and SN38G in human and porcine plasma by ultra high-performance liquid chromatography-tandem mass spectrometry and its application to hepatic chemoembolization. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22305081/),%,2.4 to 2.8,207751,DB01124,Tolbutamide
,25618252,flow rate,"After one-step liquid-liquid extraction (LLE) using methyl tert-butyl ether (MTBE), pelubiprofen, M-D, and tolbutamide (the internal standard, IS) were eluted from a Capcellpak C18 ACR column using a gradient mobile phase consisting of 0.1% formic acid in water and acetonitrile at a flow rate 0.35mL/min.","Development and validation of an LC-MS/MS method for the determination of pelubiprofen and its active metabolite, trans-alcohol, in human plasma and its application to pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25618252/),[ml] / [min],0.35,214210,DB01124,Tolbutamide
>,25618252,S/N,The achieved lower limits of quantitation (LLOQ) of pelubiprofen and M-D were both 15ng/mL (S/N>10) and the standard calibration curves for pelubiprofen and M-D were linear (correlation coefficients >0.99) over the studied concentration range (15-2000ng/mL).,"Development and validation of an LC-MS/MS method for the determination of pelubiprofen and its active metabolite, trans-alcohol, in human plasma and its application to pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25618252/),,10,214211,DB01124,Tolbutamide
,28925888,g,"The optimal SNEDDS formulation having mean globule diameter, viscosity, polydispersity 58.55 ± 0.2 nm, 26.18 ± 0.2 cps, 0.277 respectively, and infinite dilution capability displayed a highly significant increase in dissolution rate within 5 h compared to pure drug suspension.","A Self-nanoemulsifying Drug Delivery System for Poorly Water Soluble Tolbutamide: Development, Optimization and Pharmacodynamic Studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28925888/),nm,58.55,219874,DB01124,Tolbutamide
,28925888,viscosity,"The optimal SNEDDS formulation having mean globule diameter, viscosity, polydispersity 58.55 ± 0.2 nm, 26.18 ± 0.2 cps, 0.277 respectively, and infinite dilution capability displayed a highly significant increase in dissolution rate within 5 h compared to pure drug suspension.","A Self-nanoemulsifying Drug Delivery System for Poorly Water Soluble Tolbutamide: Development, Optimization and Pharmacodynamic Studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28925888/),cps,26.18,219875,DB01124,Tolbutamide
,28925888,polydispersity,"The optimal SNEDDS formulation having mean globule diameter, viscosity, polydispersity 58.55 ± 0.2 nm, 26.18 ± 0.2 cps, 0.277 respectively, and infinite dilution capability displayed a highly significant increase in dissolution rate within 5 h compared to pure drug suspension.","A Self-nanoemulsifying Drug Delivery System for Poorly Water Soluble Tolbutamide: Development, Optimization and Pharmacodynamic Studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28925888/),nm,58.55,219876,DB01124,Tolbutamide
,16698161,Ki,"The whole PSP extract had a Ki value of 12.6 microM and IC50 at 18.4 microM, while the water extract had a Ki value of 6.9 microM and IC50 at 9.8 microM.",Polysaccharide peptides from COV-1 strain of Coriolus versicolor inhibit tolbutamide 4-hydroxylation in the rat in vitro and in vivo. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16698161/),μM,12.6,220571,DB01124,Tolbutamide
,16698161,IC50,"The whole PSP extract had a Ki value of 12.6 microM and IC50 at 18.4 microM, while the water extract had a Ki value of 6.9 microM and IC50 at 9.8 microM.",Polysaccharide peptides from COV-1 strain of Coriolus versicolor inhibit tolbutamide 4-hydroxylation in the rat in vitro and in vivo. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16698161/),μM,18.4,220572,DB01124,Tolbutamide
,16698161,Ki,"The whole PSP extract had a Ki value of 12.6 microM and IC50 at 18.4 microM, while the water extract had a Ki value of 6.9 microM and IC50 at 9.8 microM.",Polysaccharide peptides from COV-1 strain of Coriolus versicolor inhibit tolbutamide 4-hydroxylation in the rat in vitro and in vivo. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16698161/),μM,6.9,220573,DB01124,Tolbutamide
,16698161,IC50,"The whole PSP extract had a Ki value of 12.6 microM and IC50 at 18.4 microM, while the water extract had a Ki value of 6.9 microM and IC50 at 9.8 microM.",Polysaccharide peptides from COV-1 strain of Coriolus versicolor inhibit tolbutamide 4-hydroxylation in the rat in vitro and in vivo. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16698161/),μM,9.8,220574,DB01124,Tolbutamide
,16698161,Ki,"Sulphaphenazole, a specific human CYP2C9 inhibitor, showed a Ki value of 30.8 microM and IC50 at 44.0 microM in the test system.",Polysaccharide peptides from COV-1 strain of Coriolus versicolor inhibit tolbutamide 4-hydroxylation in the rat in vitro and in vivo. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16698161/),μM,30.8,220575,DB01124,Tolbutamide
,16698161,IC50,"Sulphaphenazole, a specific human CYP2C9 inhibitor, showed a Ki value of 30.8 microM and IC50 at 44.0 microM in the test system.",Polysaccharide peptides from COV-1 strain of Coriolus versicolor inhibit tolbutamide 4-hydroxylation in the rat in vitro and in vivo. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16698161/),μM,44.0,220576,DB01124,Tolbutamide
,27222609,flow rate,"Chromatographic separation of the analytes was performed on the YMC pack ODS AM (150 mm × 4.6 mm, 5 µm) column under gradient conditions with methanol: 2.0 mM ammonium acetate buffer as the mobile phases at a flow rate of 1 mL/min.",Simultaneous Quantification of Baricitinib and Methotrexate in Rat Plasma by LC-MS/MS: Application to a Pharmacokinetic Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27222609/),[ml] / [min],1,220894,DB01124,Tolbutamide
,27222609,extraction recoveries,"Mean extraction recoveries for baricitinib, methotrexate, and IS of 86.8%, 89.4%, and 91.8% were consistent across low, medium, and high QC levels, respectively.",Simultaneous Quantification of Baricitinib and Methotrexate in Rat Plasma by LC-MS/MS: Application to a Pharmacokinetic Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27222609/),%,86.8,220895,DB01124,Tolbutamide
,27222609,extraction recoveries,"Mean extraction recoveries for baricitinib, methotrexate, and IS of 86.8%, 89.4%, and 91.8% were consistent across low, medium, and high QC levels, respectively.",Simultaneous Quantification of Baricitinib and Methotrexate in Rat Plasma by LC-MS/MS: Application to a Pharmacokinetic Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27222609/),%,89.4,220896,DB01124,Tolbutamide
,27222609,extraction recoveries,"Mean extraction recoveries for baricitinib, methotrexate, and IS of 86.8%, 89.4%, and 91.8% were consistent across low, medium, and high QC levels, respectively.",Simultaneous Quantification of Baricitinib and Methotrexate in Rat Plasma by LC-MS/MS: Application to a Pharmacokinetic Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27222609/),%,91.8,220897,DB01124,Tolbutamide
less,32738202,Ki,The Ki values in this study were less than 8.32 μM.,Evaluation of acacetin inhibition potential against cytochrome P450 in vitro and in vivo. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32738202/),μM,8.32,223492,DB01124,Tolbutamide
,8839660,AUC0(240)-,"Following tolbutamide, mean AUC0(240)-GLY values were 97.7 and 98.8 mmol.l-1.min, without or with cicletanine, respectively; the corresponding AUC0(60)-IRI were 485 and 321 mU.l-1.min.",A drug interaction study between cicletanine and tolbutamide in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8839660/),[mM·min] / [l],97.7,224327,DB01124,Tolbutamide
,8839660,AUC0(240)-,"Following tolbutamide, mean AUC0(240)-GLY values were 97.7 and 98.8 mmol.l-1.min, without or with cicletanine, respectively; the corresponding AUC0(60)-IRI were 485 and 321 mU.l-1.min.",A drug interaction study between cicletanine and tolbutamide in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8839660/),[mM·min] / [l],98.8,224328,DB01124,Tolbutamide
,8839660,AUC0(60)-IRI,"Following tolbutamide, mean AUC0(240)-GLY values were 97.7 and 98.8 mmol.l-1.min, without or with cicletanine, respectively; the corresponding AUC0(60)-IRI were 485 and 321 mU.l-1.min.",A drug interaction study between cicletanine and tolbutamide in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8839660/),[min·mu] / [l],485,224329,DB01124,Tolbutamide
,8839660,AUC0(60)-IRI,"Following tolbutamide, mean AUC0(240)-GLY values were 97.7 and 98.8 mmol.l-1.min, without or with cicletanine, respectively; the corresponding AUC0(60)-IRI were 485 and 321 mU.l-1.min.",A drug interaction study between cicletanine and tolbutamide in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8839660/),[min·mu] / [l],321,224330,DB01124,Tolbutamide
,8839660,peak glycaemia,Mean peak glycaemia values were 0.996 and 1.071 mmol.l-1.,A drug interaction study between cicletanine and tolbutamide in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8839660/),[mM] / [l],0.996,224331,DB01124,Tolbutamide
,8839660,peak glycaemia,Mean peak glycaemia values were 0.996 and 1.071 mmol.l-1.,A drug interaction study between cicletanine and tolbutamide in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8839660/),[mM] / [l],1.071,224332,DB01124,Tolbutamide
,8839660,peak IRI,"Regarding the peak IRI, a decrease was observed after tolbutamide and cicletanine: median values were 29.2 and 17.4 mU.l-1.",A drug interaction study between cicletanine and tolbutamide in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8839660/),[mu] / [l],29.2,224333,DB01124,Tolbutamide
,8839660,peak IRI,"Regarding the peak IRI, a decrease was observed after tolbutamide and cicletanine: median values were 29.2 and 17.4 mU.l-1.",A drug interaction study between cicletanine and tolbutamide in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8839660/),[mu] / [l],17.4,224334,DB01124,Tolbutamide
,8839660,time to peak glycaemia,The corresponding median time to peak glycaemia and IRI values were 30 and 30 min and 5 (all subjects) and 5 min.,A drug interaction study between cicletanine and tolbutamide in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8839660/),min,30,224335,DB01124,Tolbutamide
,8839660,IRI,The corresponding median time to peak glycaemia and IRI values were 30 and 30 min and 5 (all subjects) and 5 min.,A drug interaction study between cicletanine and tolbutamide in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8839660/),min,30,224336,DB01124,Tolbutamide
,8839660,IRI,The corresponding median time to peak glycaemia and IRI values were 30 and 30 min and 5 (all subjects) and 5 min.,A drug interaction study between cicletanine and tolbutamide in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8839660/),min,5,224337,DB01124,Tolbutamide
,12061540,Ki,"The mean Ki values of KTZ were 10.6+/-6.0, 170+/-2.5, and 0.180+/-0.131 microM for 7-ethoxyresorufin O-deethylation, tolbutamide methylhydroxylation, and midazolam 4-hydroxylation, respectively.",In vitro characterization of the inhibitory effects of ketoconazole on metabolic activities of cytochrome P-450 in canine hepatic microsomes. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12061540/),μM,10.6,224594,DB01124,Tolbutamide
,12061540,Ki,"The mean Ki values of KTZ were 10.6+/-6.0, 170+/-2.5, and 0.180+/-0.131 microM for 7-ethoxyresorufin O-deethylation, tolbutamide methylhydroxylation, and midazolam 4-hydroxylation, respectively.",In vitro characterization of the inhibitory effects of ketoconazole on metabolic activities of cytochrome P-450 in canine hepatic microsomes. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12061540/),μM,170,224595,DB01124,Tolbutamide
,12061540,Ki,"The mean Ki values of KTZ were 10.6+/-6.0, 170+/-2.5, and 0.180+/-0.131 microM for 7-ethoxyresorufin O-deethylation, tolbutamide methylhydroxylation, and midazolam 4-hydroxylation, respectively.",In vitro characterization of the inhibitory effects of ketoconazole on metabolic activities of cytochrome P-450 in canine hepatic microsomes. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12061540/),μM,0.180,224596,DB01124,Tolbutamide
,22695883,recoveries,The recoveries ranged from 67.5% to 98.5%.,"UPLC-MS-MS method for simultaneous determination of caffeine, tolbutamide, metoprolol, and dapsone in rat plasma and its application to cytochrome P450 activity study in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22695883/),%,67.5,224839,DB01124,Tolbutamide
,22695883,recoveries,The recoveries ranged from 67.5% to 98.5%.,"UPLC-MS-MS method for simultaneous determination of caffeine, tolbutamide, metoprolol, and dapsone in rat plasma and its application to cytochrome P450 activity study in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22695883/),%,98.5,224840,DB01124,Tolbutamide
,30443705,"Cav,ss","Clinically relevant nitisinone steady-state concentrations were reached after 12 days: mean Cav,ss of 94.08 μM.","Non randomized study on the potential of nitisinone to inhibit cytochrome P450 2C9, 2D6, 2E1 and the organic anion transporters OAT1 and OAT3 in healthy volunteers. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30443705/),μM,94.08,230404,DB01124,Tolbutamide
,10366903,RSD%,RSD% of 0.5% have become standard for quality control assays.,Pharmacokinetic investigations with direct injection of plasma samples: possible savings using capillary electrophoresis (CE). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10366903/),%,0.5,236201,DB01124,Tolbutamide
,10366903,total analysis time,"A number of pharmaceuticals (e.g. acetaminophen, salicylic acid, sulfamethoxazole, theophylline, tolbutamide, and trimethoprim) have been determined in human plasma on underivatized fused silica capillaries by MEKC without sample pretreatment, the total analysis time being only 10 min.",Pharmacokinetic investigations with direct injection of plasma samples: possible savings using capillary electrophoresis (CE). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10366903/),min,10,236202,DB01124,Tolbutamide
,10366903,detection limit,"The separation system is tested in a concentration range between 10 ng/mL and 100 micrograms/mL, the detection limit being about 5 ng/mL.",Pharmacokinetic investigations with direct injection of plasma samples: possible savings using capillary electrophoresis (CE). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10366903/),[ng] / [ml],5,236203,DB01124,Tolbutamide
,3871765,half-life,Fluoxetine disappears from plasma with a half-life of 1-3 days; its metabolite norfluoxetine has a plasma half-life of 7-15 days.,Fluoxetine: clinical pharmacology and physiologic disposition. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3871765/),d,1-3,240991,DB01124,Tolbutamide
,3871765,plasma half-life,Fluoxetine disappears from plasma with a half-life of 1-3 days; its metabolite norfluoxetine has a plasma half-life of 7-15 days.,Fluoxetine: clinical pharmacology and physiologic disposition. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3871765/),d,7-15,240992,DB01124,Tolbutamide
,3383988,half-life,Sulphaphenazole produced a significant increase in the half-life of tolbutamide (7.10 to 21.50 h) and a corresponding decrease in its clearance (0.260 to 0.084 ml.min-1.kg-1).,"Selective inhibition of drug oxidation after simultaneous administration of two probe drugs, antipyrine and tolbutamide. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3383988/),h,7.10 to 21.50,243330,DB01124,Tolbutamide
,3383988,clearance,Sulphaphenazole produced a significant increase in the half-life of tolbutamide (7.10 to 21.50 h) and a corresponding decrease in its clearance (0.260 to 0.084 ml.min-1.kg-1).,"Selective inhibition of drug oxidation after simultaneous administration of two probe drugs, antipyrine and tolbutamide. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3383988/),[ml] / [kg·min],0.260 to 0.084,243331,DB01124,Tolbutamide
,3383988,half lives,"However, a 1.6-times higher dose of cimetidine did increase the half lives both of tolbutamide and antipyrine (6.21 to 9.04 h and 14.2 to 19.2 h, respectively) and decrease their clearance (0.226 to 0.148 and 0.50 to 0.31 ml.min-1 kg-1, respectively).","Selective inhibition of drug oxidation after simultaneous administration of two probe drugs, antipyrine and tolbutamide. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3383988/),h,6.21 to 9.04,243332,DB01124,Tolbutamide
,3383988,half lives,"However, a 1.6-times higher dose of cimetidine did increase the half lives both of tolbutamide and antipyrine (6.21 to 9.04 h and 14.2 to 19.2 h, respectively) and decrease their clearance (0.226 to 0.148 and 0.50 to 0.31 ml.min-1 kg-1, respectively).","Selective inhibition of drug oxidation after simultaneous administration of two probe drugs, antipyrine and tolbutamide. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3383988/),h,14.2 to 19.2,243333,DB01124,Tolbutamide
,3383988,clearance,"However, a 1.6-times higher dose of cimetidine did increase the half lives both of tolbutamide and antipyrine (6.21 to 9.04 h and 14.2 to 19.2 h, respectively) and decrease their clearance (0.226 to 0.148 and 0.50 to 0.31 ml.min-1 kg-1, respectively).","Selective inhibition of drug oxidation after simultaneous administration of two probe drugs, antipyrine and tolbutamide. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3383988/),[ml] / [kg·min],0.226 to 0.148,243334,DB01124,Tolbutamide
,3383988,clearance,"However, a 1.6-times higher dose of cimetidine did increase the half lives both of tolbutamide and antipyrine (6.21 to 9.04 h and 14.2 to 19.2 h, respectively) and decrease their clearance (0.226 to 0.148 and 0.50 to 0.31 ml.min-1 kg-1, respectively).","Selective inhibition of drug oxidation after simultaneous administration of two probe drugs, antipyrine and tolbutamide. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3383988/),[ml] / [kg·min],0.50 to 0.31,243335,DB01124,Tolbutamide
,3383988,half-life,A single dose of primaquine had no demonstrable effect on tolbutamide disposition whereas the half-life of antipyrine was increased (12.1 to 15.0 h) and its clearance decreased (0.63 to 0.38 ml.min-1.kg-1).,"Selective inhibition of drug oxidation after simultaneous administration of two probe drugs, antipyrine and tolbutamide. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3383988/),h,12.1 to 15.0,243336,DB01124,Tolbutamide
,3383988,clearance,A single dose of primaquine had no demonstrable effect on tolbutamide disposition whereas the half-life of antipyrine was increased (12.1 to 15.0 h) and its clearance decreased (0.63 to 0.38 ml.min-1.kg-1).,"Selective inhibition of drug oxidation after simultaneous administration of two probe drugs, antipyrine and tolbutamide. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3383988/),[ml] / [kg·min],0.63 to 0.38,243337,DB01124,Tolbutamide
,757962,flow-rate,A mu Bondapak C18 reversed-phase column was used with a mobile phase acetonitrile--0.05% phosphoric acid (45:55) at a flow-rate of 1.5 ml/min.,"Simple, rapid and micro high-pressure liquid chromatographic method for the simultaneous determination of tolbutamide and carboxy tolbutamide in plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/757962/),[ml] / [min],1.5,244708,DB01124,Tolbutamide
,757962,retention times,"Tolbutamide and its metabolite had retention times of 5.75 and 3.25 min, respectively.","Simple, rapid and micro high-pressure liquid chromatographic method for the simultaneous determination of tolbutamide and carboxy tolbutamide in plasma. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/757962/),min,5.75,244709,DB01124,Tolbutamide
,757962,retention times,"Tolbutamide and its metabolite had retention times of 5.75 and 3.25 min, respectively.","Simple, rapid and micro high-pressure liquid chromatographic method for the simultaneous determination of tolbutamide and carboxy tolbutamide in plasma. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/757962/),min,3.25,244710,DB01124,Tolbutamide
,30048731,recoveries,The intra and inter-assay accuracy and precision of the method were within ± 14.9% and the recoveries ranged from 83.2% to 106.1%.,"Effects of Baoyuan decoction, a traditional Chinese medicine formula, on the activities and mRNA expression of seven CYP isozymes in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30048731/),%,83.2,244934,DB01124,Tolbutamide
,30048731,recoveries,The intra and inter-assay accuracy and precision of the method were within ± 14.9% and the recoveries ranged from 83.2% to 106.1%.,"Effects of Baoyuan decoction, a traditional Chinese medicine formula, on the activities and mRNA expression of seven CYP isozymes in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30048731/),%,106.1,244935,DB01124,Tolbutamide
,3803421,unbound hydroxylation clearance rate,"Cimetidine had no effect on the disposition of tolbutamide, including the unbound hydroxylation clearance rate (324 ml X min-1, tolbutamide alone; 316 ml X min-1, tolbutamide plus cimetidine).",Lack of inhibition of tolbutamide hydroxylation by cimetidine in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3803421/),[ml] / [min],324,245126,DB01124,Tolbutamide
,3803421,unbound hydroxylation clearance rate,"Cimetidine had no effect on the disposition of tolbutamide, including the unbound hydroxylation clearance rate (324 ml X min-1, tolbutamide alone; 316 ml X min-1, tolbutamide plus cimetidine).",Lack of inhibition of tolbutamide hydroxylation by cimetidine in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3803421/),[ml] / [min],316,245127,DB01124,Tolbutamide
,3803421,total urinary recovery,The total urinary recovery of carboxy- and hydroxy-tolbutamide metabolites was 85.7 +/- 20.3% of the dose when tolbutamide was given alone and 78.9 +/- 14.3% when given with cimetidine.,Lack of inhibition of tolbutamide hydroxylation by cimetidine in man. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3803421/),%,85.7,245128,DB01124,Tolbutamide
,3803421,total urinary recovery,The total urinary recovery of carboxy- and hydroxy-tolbutamide metabolites was 85.7 +/- 20.3% of the dose when tolbutamide was given alone and 78.9 +/- 14.3% when given with cimetidine.,Lack of inhibition of tolbutamide hydroxylation by cimetidine in man. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3803421/),%,78.9,245129,DB01124,Tolbutamide
,21394449,detection limits,The detection limits (signal-to-noise ratio = 3) was as low as 0.1-2 ng/mL.,High-throughput and simultaneous analysis of eight central-acting muscle relaxants in human plasma by ultra-performance liquid chromatography-tandem mass spectrometry in the positive and negative ionization modes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21394449/),[ng] / [ml],3,254532,DB01124,Tolbutamide
,21394449,detection limits,The detection limits (signal-to-noise ratio = 3) was as low as 0.1-2 ng/mL.,High-throughput and simultaneous analysis of eight central-acting muscle relaxants in human plasma by ultra-performance liquid chromatography-tandem mass spectrometry in the positive and negative ionization modes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21394449/),[ng] / [ml],0.1-2,254533,DB01124,Tolbutamide
,21394449,signal-to-noise ratio,The detection limits (signal-to-noise ratio = 3) was as low as 0.1-2 ng/mL.,High-throughput and simultaneous analysis of eight central-acting muscle relaxants in human plasma by ultra-performance liquid chromatography-tandem mass spectrometry in the positive and negative ionization modes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21394449/),[ng] / [ml],3,254534,DB01124,Tolbutamide
,21394449,signal-to-noise ratio,The detection limits (signal-to-noise ratio = 3) was as low as 0.1-2 ng/mL.,High-throughput and simultaneous analysis of eight central-acting muscle relaxants in human plasma by ultra-performance liquid chromatography-tandem mass spectrometry in the positive and negative ionization modes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21394449/),[ng] / [ml],0.1-2,254535,DB01124,Tolbutamide
,19369937,total apparent clearances (Cl/F),"Mean total apparent clearances (Cl/F) in the genotype groups CYP2C9*1/*1, *1/*2, *1/*3, *2/*3, and *3/*3 before rifampin were 0.78, 0.74, 0.52, 0.40, and 0.13 l/h, respectively.",Relative impact of genotype and enzyme induction on the metabolic capacity of CYP2C9 in healthy volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19369937/),[l] / [h],0.78,266363,DB01124,Tolbutamide
,19369937,total apparent clearances (Cl/F),"Mean total apparent clearances (Cl/F) in the genotype groups CYP2C9*1/*1, *1/*2, *1/*3, *2/*3, and *3/*3 before rifampin were 0.78, 0.74, 0.52, 0.40, and 0.13 l/h, respectively.",Relative impact of genotype and enzyme induction on the metabolic capacity of CYP2C9 in healthy volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19369937/),[l] / [h],0.74,266364,DB01124,Tolbutamide
,19369937,total apparent clearances (Cl/F),"Mean total apparent clearances (Cl/F) in the genotype groups CYP2C9*1/*1, *1/*2, *1/*3, *2/*3, and *3/*3 before rifampin were 0.78, 0.74, 0.52, 0.40, and 0.13 l/h, respectively.",Relative impact of genotype and enzyme induction on the metabolic capacity of CYP2C9 in healthy volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19369937/),[l] / [h],0.52,266365,DB01124,Tolbutamide
,19369937,total apparent clearances (Cl/F),"Mean total apparent clearances (Cl/F) in the genotype groups CYP2C9*1/*1, *1/*2, *1/*3, *2/*3, and *3/*3 before rifampin were 0.78, 0.74, 0.52, 0.40, and 0.13 l/h, respectively.",Relative impact of genotype and enzyme induction on the metabolic capacity of CYP2C9 in healthy volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19369937/),[l] / [h],0.40,266366,DB01124,Tolbutamide
,19369937,total apparent clearances (Cl/F),"Mean total apparent clearances (Cl/F) in the genotype groups CYP2C9*1/*1, *1/*2, *1/*3, *2/*3, and *3/*3 before rifampin were 0.78, 0.74, 0.52, 0.40, and 0.13 l/h, respectively.",Relative impact of genotype and enzyme induction on the metabolic capacity of CYP2C9 in healthy volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19369937/),[l] / [h],0.13,266367,DB01124,Tolbutamide
,7586950,Michaelis-Menten constants,"In human liver microsomes, the kinetics of P450-catalyzed N-oxidation of dapsone were biphasic, with the Michaelis-Menten constants of 0.14 +/- 0.05 and 0.004 +/- 0.003 mmol/L and the respective maximum velocities of 1.3 +/- 0.1 and 0.13 +/- 0.04 nmol/mg protein/min (mean +/- SEM).",Metabolism of dapsone to its hydroxylamine by CYP2E1 in vitro and in vivo. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7586950/),[mM] / [l],0.14,274074,DB01124,Tolbutamide
,7586950,Michaelis-Menten constants,"In human liver microsomes, the kinetics of P450-catalyzed N-oxidation of dapsone were biphasic, with the Michaelis-Menten constants of 0.14 +/- 0.05 and 0.004 +/- 0.003 mmol/L and the respective maximum velocities of 1.3 +/- 0.1 and 0.13 +/- 0.04 nmol/mg protein/min (mean +/- SEM).",Metabolism of dapsone to its hydroxylamine by CYP2E1 in vitro and in vivo. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7586950/),[mM] / [l],0.004,274075,DB01124,Tolbutamide
,7586950,maximum velocities,"In human liver microsomes, the kinetics of P450-catalyzed N-oxidation of dapsone were biphasic, with the Michaelis-Menten constants of 0.14 +/- 0.05 and 0.004 +/- 0.003 mmol/L and the respective maximum velocities of 1.3 +/- 0.1 and 0.13 +/- 0.04 nmol/mg protein/min (mean +/- SEM).",Metabolism of dapsone to its hydroxylamine by CYP2E1 in vitro and in vivo. ,Vmax velocity-Q2,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7586950/),[nM] / [·mg·min],1.3,274076,DB01124,Tolbutamide
,7586950,maximum velocities,"In human liver microsomes, the kinetics of P450-catalyzed N-oxidation of dapsone were biphasic, with the Michaelis-Menten constants of 0.14 +/- 0.05 and 0.004 +/- 0.003 mmol/L and the respective maximum velocities of 1.3 +/- 0.1 and 0.13 +/- 0.04 nmol/mg protein/min (mean +/- SEM).",Metabolism of dapsone to its hydroxylamine by CYP2E1 in vitro and in vivo. ,Vmax velocity-Q2,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7586950/),[nM] / [·mg·min],0.13,274077,DB01124,Tolbutamide
